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Background: Pain of lumbar facet-joint origin is a common cause of low back pain in adults and may lead
to chronic pain and disability, with associated health and socioeconomic implications. The socioeconomic
burden includes an inability to return to work resulting in loss of productivity in addition to direct and
indirect health-care utilisation costs. Lumbar facet-joints are paired synovial joints between the superior
and inferior articular processes of consecutive lumbar vertebrae and between the fifth lumbar vertebra and
the sacrum. Facet-joint pain is defined as pain that arises from any structure that is part of the facet-joints,
including the fibrous capsule, synovial membrane, hyaline cartilage and bone. This pain may be treated
by intra-articular injections with local anaesthetic and steroid, although this treatment is not standardised.
At present, there is no definitive research to support the use of targeted lumbar facet-joint injections to
manage this pain. Because of the lack of high-quality, robust clinical evidence, the National Institute for
Health and Care Excellence (NICE) guidelines on the management of chronic low back pain [NICE. Low
Back Pain in Adults: Early Management. Clinical guideline (CG88). London: NICE; 2009] did not
recommend the use of spinal injections despite their perceived potential to reduce pain intensity and
improve rehabilitation, with NICE calling for further research to be undertaken. The updated guidelines
[NICE. Low Back Pain and Sciatica in Over 16s: Assessment and Management. NICE guideline (NG59).
London: NICE; 2016] again do not recommend the use of spinal injections.
Objectives: To assess the feasibility of carrying out a definitive study to evaluate the clinical effectiveness
and cost-effectiveness of lumbar facet-joint injections compared with a sham procedure in patients with
non-specific low back pain of > 3 months’ duration.
Design: Blinded parallel two-arm pilot randomised controlled trial.
Setting: Initially planned as a multicentre study involving three NHS trusts in the UK, recruitment took
place in the pain and spinal orthopaedic clinics at Barts Health NHS Trust only.
Participants: Adult patients referred by their GP to the specialist clinics with non-specific low back pain of
at least 3 months’ duration despite NICE-recommended best non-invasive care (education and one of a
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physical exercise programme, acupuncture or manual therapy). Patients who had already received lumbar
facet-joint injections or who had had previous back surgery were excluded.
Interventions: Participants who had a positive result following a diagnostic test (single medial branch
nerve blocks) were randomised and blinded to receive either intra-articular lumbar facet-joint injections
with steroids (intervention group) or a sham procedure (control group). All participants were invited to
attend a group-based combined physical and psychological (CPP) programme.
Main outcome measures: In addition to the primary outcome of feasibility, questionnaires were used to
assess a range of pain-related (including the Brief Pain Inventory and Short-Form McGill Pain Questionnaire
version 2) and disability-related (including the EuroQol-5 Dimensions five-level version and Oswestry Low
Back Pain Questionnaire) issues. Health-care utilisation and cost data were also assessed. The questionnaire
visits took place at baseline and at 6 weeks, 3 months and 6 months post randomisation. The outcome
assessors were blinded to the allocation groups.
Results: Of 628 participants screened for eligibility, nine were randomised to receive the study intervention
(intervention group, n = 5; sham group, n = 4), six completed the CPP programme and eight completed
the study.
Limitations: Failure to achieve our expected recruitment targets led to early closure of the study by
the funder.
Conclusions: Because of the small number of participants recruited to the study, we were unable to draw
any conclusions about the clinical effectiveness or cost-effectiveness of intra-articular lumbar facet-joint
injections in the management of non-specific low back pain. Although we did not achieve the target
recruitment rate from the pain clinics, we demonstrated our ability to develop a robust study protocol and
deliver the intended interventions safely to all nine randomised participants, thus addressing many of the
feasibility objectives.
Future work: Stronger collaborations with primary care may improve the recruitment of patients earlier in
their pain trajectory who are suitable for inclusion in a future trial.
Trial registration: EudraCT 2014-003187-20 and Current Controlled Trials ISRCTN12191542.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 21, No. 74.
See the NIHR Journals Library website for further project information.
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Glossary
Best usual care As described in National Institute for Health and Care Excellence clinical guideline 88,
Low Back Pain: Early Management of Persistent Non-specific Low Back Pain, best usual care includes
providing patients with advice and information to promote self-management of their low back pain and
offering one of the following treatments, taking into account patient preference: an exercise programme,
a course of manual therapy or a course of acupuncture.
Combined physical and psychological programme A group-based programme focused around
education and targeted training of self-management skills, utilising a psychological approach to improve
physical activity and functioning.
Definitive study An adequately powered randomised controlled trial to provide unequivocal evidence
that supports or rejects the test hypothesis, for example whether or not a treatment shows a benefit
to patients.
Feasibility study A study that asks whether or not something can be done, whether or not we should
proceed with it and, if so, how.
Lumbar facet-joint injections The active intervention in which a needle is inserted into the facet-joint
and a therapeutic substance, such as a steroid, is injected.
Sham procedure A dummy procedure in which a needle is inserted near the facet-joint but no
therapeutic substance is injected.
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Plain English summary
Lumbar facet-joints are small, paired joints in the lower back that provide stability, integrity and flexibilityof movement of the spine. Diseased facet-joints may cause persistent low back pain. The current
treatment options available in the UK include so-called lumbar facet-joint injections, when a needle is
inserted into the joint and a therapeutic substance is injected. However, there is insufficient high-quality
evidence to support their use and for this reason they were not approved in the latest national guidelines
on the management of persistent low back pain.
This study aimed to see whether a large-scale study to assess lumbar facet-joint injections with steroid
compared with a dummy or ‘sham’ procedure (a needle is inserted near the facet-joint but no therapeutic
substance is injected) was possible.
We recruited patients with persistent low back pain from the pain clinics at Barts Health NHS Trust; those
suitable to take part were randomly allocated to receive either lumbar facet-joint injections or a sham
procedure. All participants were also invited to attend a combined physical and psychological programme
consisting of six sessions of a psychologically informed group-based intervention of education and training,
each lasting for 90 minutes, recommended as a strategy to reduce pain and its impact on a person’s
day-to-day life. Participants completed questionnaires about their pain and disability up until 6 months
after their injections. Eight participants (the target estimate was 48 participants) completed the study
before it was terminated by the funder.
We were unable to recruit the anticipated number of patients to the study as those attending the hospital
pain clinics were not suitable for reasons such as they had received previous facet-joint injections or they
were experiencing severe pain elsewhere other than the back. We therefore could not tell whether or not
facet-joint injections are able to reduce low back pain or whether or not they are cost-effective. We were
otherwise able to deliver the study as planned and without any significant problems.
We believe that it may be feasible to progress to a large-scale trial comparing facet-joint injections against
a sham procedure by recruiting patients from other sources such as general practitioner surgeries.
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Scientific summary
Background
The Global Burden of Disease Study (GBD 2015 Disease and Injury Incidence and Prevalence Collaborators.
Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries,
1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388:1545–1602)
has concluded that low back pain (LBP) causes more disability in the world than any other condition. LBP
has a high lifetime prevalence, with significant economic and societal costs.
Common contributors to LBP in adults are thought to include lumbar facet-joints; treatment options for
LBP with a likely facet-joint component include intra-articular facet-joint injections (FJIs), medial branch
nerve blocks (which innervate the joints) or radiofrequency denervation of the medial branch nerves.
Although the technique of lumbar FJI is not standardised, this typically involves injection of an active
substance such as a corticosteroid into the joint.
The National Institute for Health and Care Excellence (NICE) guidelines for managing LBP were recently
updated [NICE. Low Back Pain and Sciatica in Over 16s: Assessment and Management. NICE guideline
(NG59). London: NICE; 2016] and do not recommend intra-articular FJIs on the grounds of there being
insufficient high-quality evidence to support their use, recommending instead targeting the nerve supply
of the facet-joints as the predominant pain generator source. Despite these recommendations, intra-articular
FJIs remain in common use.
Review of the literature: a review of systematic reviews and meta-analyses
We undertook a literature search to identify systematic reviews and meta-analyses of randomised
controlled trials of intra-articular lumbar FJIs for chronic LBP. Eleven systematic reviews met the inclusion
criteria and their methodological quality was assessed using the Assessment of Multiple Systematic Reviews
(AMSTAR) checklist. Although 14 randomised controlled trials were identified across these reviews, no one
review included all of these trials. The authors of these systematic reviews concluded that the level of
clinical heterogeneity across included randomised controlled trials precluded any meta-analyses.
The conclusions drawn from the systematic reviews were generally equivocal. The limited to moderate
quality of evidence to support the effectiveness of therapeutic lumbar FJIs in the management of chronic
LBP indicates a need for further high-quality research in this area.
Rationale for a feasibility study
Because of the lack of high-quality, robust clinical evidence, the National Institute for Health Research (NIHR)
Health Technology Assessment (HTA) programme issued a commissioning brief in 2011 to answer the research
question, ‘Is a definitive study to assess the effectiveness and cost-effectiveness of facet-joint injections
compared with best non-invasive care for people with persistent non-specific low back pain feasible?’.
Objectives
We aimed to assess the feasibility of conducting a definitive study to evaluate the clinical effectiveness and
cost-effectiveness of FJIs compared with a sham procedure in patients with non-specific LBP of > 3 months’
duration. Specific objectives were to:
l assess the eligibility criteria and recruitment and retention of patients in the two treatment arms
(FJIs vs. sham procedure) by assessing the feasibility of recruitment to inform a potential definitive study
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l assess the feasibility and acceptability of the two treatment arms from the point of view of patients and
their pain teams
l assess the feasibility of the proposed definitive study design including testing of the randomisation and
blinding procedures, development of an appropriate active and sham procedure for FJIs and assessment
of the consistency of the trial sites in terms of delivering the combined physical and psychological (CPP)
programme and their ability to collect the outcomes proposed for the main trial
l estimate outcome standard deviations (SDs) to inform the power calculation for a definitive study
l finalise the protocol design, statistical plan, number of centres required and study duration for the
definitive study.
Methods
Study design
This feasibility study utilised a blinded parallel two-arm pilot randomised controlled trial design. A
multicentre design was planned, with patients recruited from pain clinics at three participating NHS centres
and their associated community-based pain clinics; however, recruitment took place at a single centre,
Barts Health NHS Trust.
Participants
The study sought patients referred by their general practitioner (GP) to the pain and spinal orthopaedic
clinics who had non-specific LBP of at least 3 months’ duration and clinical indicators for pain of facet-joint
origin, despite receiving at least two components of NICE-recommended best non-invasive care, including
education and one of a physical exercise programme, acupuncture or manual therapy. Patients who had
already received lumbar FJIs or who had had previous spinal surgery were excluded.
Following a positive diagnostic medial branch nerve block with lidocaine (> 50% pain relief on a numerical
rating scale lasting for > 30 minutes), eligible participants were individually randomised in a 1 : 1 ratio to
receive either the FJI (intervention group) or a sham (placebo injection) procedure (control group). The
intervention group received intra-articular lumbar FJIs with local anaesthetic and steroid, whereas the sham
group received periarticular injections with normal saline.
Both the intervention group and the control group received a CPP programme after their active or sham
injections. At the time of establishing this study, NICE clinical guideline CG88 (2009) had recommended a
CPP programme as part of best usual care.
Sample size calculation
At the outset of the study it was expected that a total of 60 patients would be recruited, to be able to
estimate the precision of an assumed 20% attrition rate with an error of ±5% at the 95% confidence
level. Assuming that 24 full data sets per arm were completed at the end of the study, this would give a
reasonable estimate of the variance of outcomes.
Outcomes
The outcome questionnaire visits took place in research nurse-led clinics at baseline (pre randomisation)
and at 6 weeks, 3 months and 6 months post randomisation. The outcome questionnaires covered a range
of pain- and disability-related issues including pain intensity and characteristics, use of co-analgesics in the
previous week, lack of efficacy or side effects of pain relief, expectation of benefit, health-related quality of
life, functional impairment, satisfaction with treatment, complications and adverse events, co-psychological
well-being, health-care utilisation and costs and impact on productivity.
SCIENTIFIC SUMMARY
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Statistical analysis
As this was a feasibility study, it was not planned to formally inferentially test differences in outcomes or
costs between or within the groups. Mean recruitment and attrition rates were calculated with 95%
confidence intervals. Means and SDs for all outcomes for the two groups at baseline and at all follow-up
visits were reported. A detailed statistical analysis plan was prepared by the study statistician prior to any
data analysis. Analyses were performed blinded to group allocation.
Health economics analysis
A health economics analysis plan was developed in collaboration with the study’s health economist and
statistician. A formal economic analysis was not proposed (as this was a feasibility study). Any outcomes
from this feasibility study would be used in the design of the definitive study. In particular, the analysis
looked at the ability to collect the outcomes proposed for the main trial.
Results
Although recruitment was planned across three centres, given the delays in study set-up the funder
directed that this take place at only one centre, Barts Health NHS Trust. Recruitment took place over
9 months, with the first participant recruited in January 2016 and the last participant recruited in
September 2016.
During the recruitment period, 628 patients referred to the recruiting clinics by their GP with non-specific
LBP were screened for eligibility to enter the study. Of the 50 patients who met the inclusion criteria,
16 agreed to take part in the study and 11 received the diagnostic test for facet-joint disease. Nine
participants had a positive response and were randomised to receive either lumbar FJIs with steroid or a
sham procedure. Eight participants completed the study; one randomised participant was lost to follow-up.
The participant screening-to-recruitment ratio was 70 : 1 (628 : 9), which contrasts with an expected
prestudy ratio of 17 : 1 (1000 : 60). The recruitment rate varied between zero and four patients per month.
The main reasons for screening failure included that patients had received previous lumbar FJIs (n = 192),
had other dominant or widespread pain (n = 92) or had radicular pain (n = 64).
Each pain consultant visit was associated with a cost of £148.03 and the delivery of the intervention or
sham procedure incurred a cost of £691 per patient. The CPP programme had a mean cost of £2500 per
patient. The intervention group was observed to have higher resource use costs than the sham group,
with a cost of £193 (SD £219) per participant in the intervention group and a cost of £75 (SD £73) per
participant in the sham group. Although there are limitations of the analysis associated with the highly
skewed costs and small sample size, this suggests that a potential downstream effect of FJI is a subsequent
increase in medication use and associated costs within primary care.
Discussion
The small number of participants recruited to the study and the feasibility design preclude us from drawing
any conclusions on the clinical effectiveness or cost-effectiveness of intra-articular lumbar FJIs in the
management of non-specific LBP. However, the clinical procedures used appeared to be safe and well
tolerated, with no significant adverse events related to the steroid injection. Furthermore, we were able to
successfully collect clinical and economic outcomes from the majority of patients over the duration of
the study.
Cost differences were identified between the intervention group and the sham group in the feasibility
study, which may be a reflection of the inherent skewness in the data and the very small sample size.
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The main weakness of the study was the failure to achieve our expected recruitment target and the
consequent early closure of the study by the funder. There were substantial system-level barriers that the
study team were unable to control, which led to long delays in obtaining research governance.
It became clear early in the recruitment phase that many patients presenting to the pain clinics with LBP of
> 3 months’ duration were not suitable for the study and that patients screened in the spinal orthopaedic
clinics also did not meet the eligibility criteria. Despite employing additional strategies in the final stages of
recruitment, we conclude that patients presenting to these hospital-based specialist clinics were generally
not suitable because of the complexity of their pain problems and that we may have had better success in
recruiting from primary care-based services.
We were unable to meet our feasibility objective of a recruitment target of 60 randomised LBP patients
across three investigative sites. Instead, we were able to randomise only nine patients at one investigative
site. However, we believe that we met our other pre-stated feasibility objectives, as detailed in the
following sections.
Assess the eligibility criteria and recruitment and retention of patients in the two
treatment arms
Recruitment took place at a single centre only, largely because of delays in study set-up and a decision by
the funder to terminate the study early because of the lack of time available to open the other two sites.
A number of reasons for the delays have been identified, including regulatory issues, staffing problems,
specific recruitment challenges, factors affecting clinician and patient participation and the study
population itself.
Assess the feasibility and acceptability of the two treatment arms from the point of
view of patients and their pain teams
A Delphi exercise was undertaken by 42 interventional pain physicians in the UK to agree on the methods
for the FJI and sham procedures; the two treatment arms can therefore be considered to be feasible and
acceptable by pain clinicians.
Of the 34 patients who met the eligibility criteria but who declined to take part in the study, none cited
the lack of acceptability of the two treatment arms as the reason for not wishing to take part.
Assess the feasibility of the proposed definitive study design
We believe that this feasibility study did allow us to demonstrate the feasibility of the study design to
inform a definitive study. We were able to develop an appropriate active injection technique and sham
procedure. No patients refused participation on the grounds of randomisation to an active or a sham
procedure. We were able to maintain the blinding of patients and clinicians. The CPP programme was
consistently delivered to small groups of participants and was well aligned to the latest NICE guidelines
(NICE, 2106).
Estimate outcome standard deviations to inform the power calculation for a
definitive study
We reported the SDs for all proposed clinical and economic outcomes at baseline and follow-up but would
express caution in using these SDs to inform the sample calculation for a future definitive study because of
the small sample size. Probably the only parameter for a future definitive study that this study was able to
estimate with precision was the screening/recruitment rate.
Finalise the protocol design, statistical plan, number of centres required and study
duration of the definitive study
Given the failure to meet the study recruitment target and the small number of patients recruited from one
centre, the study team deemed it inappropriate to present a finalised protocol for a definitive study on the
basis of this feasibility study.
SCIENTIFIC SUMMARY
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Conclusions
A successful trial can be defined as one that achieves success in recruitment and is able to answer the
research questions. Although we have successfully demonstrated our ability to develop a robust study
protocol and deliver the intended interventions, and address many of the feasibility objectives, failure to
achieve the target recruitment rate remains a key finding of this study. However, there are lessons learned
here that can be used to inform and improve patient recruitment for a future definitive study.
Two research teams were funded by the NIHR to answer the research questions: (1) the Facet Feasibility
study (the addition of intra-articular FJIs to best usual non-invasive care) (reference number HTA 11/31/01)
led by Professor Martin Underwood, University of Warwick, and (2) this project, the FACET (Feasibility of
Assessing the Clinical- and cost-Effectiveness of Therapeutic lumbar facet-joint injections) feasibility study,
led by Professor Richard Langford, Barts Health NHS Trust. Neither research team met the target recruitment
rate and Professor Underwood’s team concluded that a definitive study is indeed feasible but that recruitment
from pain clinics alone was insufficient. Both teams experienced significant delays in study set-up.
Based on our findings, we would agree with the Underwood team that a definitive study is potentially
feasible, with adjustments made to the target population and increased primary care involvement to
enable patients to be screened earlier in their pain trajectory. To optimise recruitment for a definitive study,
we would contend that any future studies in this area should involve stronger collaborations with primary
care physicians and musculoskeletal physiotherapists with the aim of making these procedures more
accessible to these patients who would not otherwise have been referred on for specialist services.
Trial registration
This trial is registered as EudraCT 2014-003187-20 and Current Controlled Trials ISRCTN12191542.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Funding history
The FACET (Feasibility of Assessing the Clinical- and cost-Effectiveness of Therapeutic lumbar facet-joint
injections) feasibility study was a commissioned proposal funded by the National Institute for Health
Research (NIHR) Health Technology Assessment (HTA) programme (reference number HTA 11/31/02);
the funding contract was agreed in July 2013. A favourable ethical opinion was given on 21 May 2015
and NHS permission was granted on 20 January 2016, with the first participant recruited to the study
on 22 January 2016. Following an extension agreement with the funder, recruitment ended on
30 September 2016 and the study closed on 31 March 2017.
Structure of this report
In this chapter, the existing evidence for therapeutic intra-articular lumbar facet-joint injections (FJIs) for
non-specific low back pain (LBP) is reviewed and the need for a pilot trial is presented. In Chapter 2 the
feasibility study procedure and associated methodological work are described, with the results of this
work being presented in Chapter 3. The implications of our findings are discussed in Chapter 4 and the
conclusions drawn with regard to a full trial are presented in Chapter 5.
Background
Low back pain causes more global disability than any other condition, and has a lifetime prevalence of up
to 85%.1 Non-specific LBP, in which symptoms are experienced without any recognisable pathology,2 is
thought to affect around 90% of all LBP sufferers, with between 1% and 5% of patients presenting
with LBP having a serious spinal pathology such as vertebral fracture, malignancy, infection and
inflammatory disease.3
The economic costs of LBP have been reported to be £12.3B per annum in the UK alone.4 Chronic LBP,
with a prevalence of 3–10%,5 is associated with depression, anxiety, deactivation, inability to work and
substantial societal costs.1,6
Common contributors to LBP in adults are thought to include lumbar facet-joints.7 These are paired
synovial joints between the superior and inferior articular processes of consecutive lumbar vertebrae and
between the fifth lumbar vertebra and the sacrum. Encapsulated nerve endings have been demonstrated
in these facet-joints, supplied by medial branches of the dorsal rami nerves (‘medial branch nerves’).
Facet-joint contributions to LBP may arise from any structure that is part of the facet-joints, including the
fibrous capsule, synovial membrane, hyaline cartilage and bone.
Low back pain with a likely facet-joint component can be treated with interventions targeting the
facet-joints, including intra-articular (within the joint itself) FJIs, periarticular medial branch nerve blocks
or radiofrequency denervation of the medial branch nerves innervating the joints. The technique of FJI
is not standardised and may be carried out with or without radiological guidance to confirm needle
placement.8 Lumbar FJIs involve the injection of an active substance, typically steroids with or without a
local anaesthetic, intra-articularly or next to the joint (periarticular injections). They are commonly carried
out under radiological or fluoroscopic guidance, although they can be performed under ultrasound or
computerised tomography scanning guidance.9
DOI: 10.3310/hta21740 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 74
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Snidvongs et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
1
The National Institute for Health and Care Excellence (NICE) guidelines for managing LBP were recently
updated [NICE guideline (NG59)10]. These guidelines propose a care pathway in which all those aged
≥ 16 years with LBP with or without sciatica should be provided with advice and information, tailored to
their needs and capabilities, to help them self-manage at all steps of the treatment pathway, including
education on the nature of LBP and sciatica and encouragement to return to work and pursue normal
activities of daily living.11 Those with a specific episode or flare-up of LBP should consider a group exercise
programme, manual treatment or a psychological therapy package. If these therapies fail, pharmacological
options and combined physical and psychological (CPP) programmes should be offered, followed by
radiofrequency denervation or surgical approaches such as fusion. The guidelines make specific ‘do not
use’ recommendations for a range of groups of treatments including acupuncture and electrotherapy;
traction, braces and corsets; disc replacement; and spinal injections (including FJIs). The NICE guidelines
omit intra-articular FJIs on the grounds of there being insufficient high-quality evidence to support their use
and recommend instead targeting the facet-joints’ nerve supply (medial branch nerves) as the predominant
pain generator source. However, intra-articular FJIs remain in common use.12
Review of the literature: a review of systematic reviews and meta-analyses
We undertook a literature search to identify systematic reviews and meta-analyses of randomised controlled
trials of intra-articular lumbar FJIs for chronic LBP. We searched MEDLINE, EMBASE and the Cochrane
Central Register of Controlled Trials from 1966 to February 2017; the search strategies used are detailed in
Appendix 1. Two reviewers (Saowarat Snidvongs and Fausto Morell-Ducos) independently screened and
assessed full-text articles for eligibility. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) flow diagram is illustrated in Figure 1. Eleven systematic reviews14–24 met the inclusion criteria; the
sources of the reviews are summarised in Appendix 2. The Assessment of Multiple Systematic Reviews
(AMSTAR) checklist,25 applied by two independent reviewers to assess the methodological quality of the
systematic reviews, demonstrated significant variations between the reviews, with AMSTAR scores ranging
between 2 and 10 out of a maximum of 11 points, as shown in Appendix 3 (a low score is associated with a
higher risk of bias).
In total, 14 randomised controlled trials were identified across these 11 reviews; 13 were obtained as
full-text articles and their findings are summarised in Table 1. Appendix 4 illustrates that, given the
variation in dates when the reviews were undertaken and their precise inclusion/exclusion criteria, no one
review included all of these trials. The authors of these systematic reviews concluded that the level of
clinical heterogeneity across the included randomised controlled trials – different injection procedures,
substances and comparators – precluded any meta-analyses.
The conclusions drawn from the systematic reviews were generally equivocal. Although there was some
trial evidence demonstrating the effectiveness of therapeutic lumbar FJIs in the management of chronic
LBP, the limited to moderate quality of this evidence was insufficient to support their use in practice.
The current evidence base for FJI is neatly summed up by a recent and high-quality systematic review by
Vekaria et al.,23 which concluded that ‘The studies found here were clinically diverse and precluded any
meta-analysis. A number of methodological issues were identified. The positive results, whilst interpreted
with caution, do suggest that there is a need for further high-quality work in this area.’23
Rationale for a feasibility study
To provide further high-quality research in this area, the NIHR HTA programme issued a commissioning
brief in 2011 to answer the research question, ‘Is a definitive study to assess the effectiveness and
cost-effectiveness of facet-joint injections compared with best non-invasive care for people with persistent
non-specific low back pain feasible?’ [see www.journalslibrary.nihr.ac.uk/programmes/hta/113102/#/
(accessed 31 October 2017)].
INTRODUCTION
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Two research teams were funded by the NIHR in response to this commissioned call: (1) the Facet Feasibility
study (the addition of intra-articular facet-joint injections to best usual non-invasive care) (reference
HTA 11/31/01) led by Professor Martin Underwood, University of Warwick [see www.journalslibrary.nihr.ac.uk/
programmes/hta/113101/#/ (accessed 31 October 2017)] and (2) this project, the FACET feasibility study
(a multicentre double-blind randomised controlled trial comparing intra-articular lumbar facet-joint injections
with a sham procedure, followed by a combined physical and psychological programme) (reference
HTA 11/31/02) [see www.journalslibrary.nihr.ac.uk/programmes/hta/113102/#/ (accessed 31 October 2017)]
led by Professor Richard Langford, Barts Health NHS Trust.
Study aims and research questions
The aim of the FACET feasibility study was to assess the feasibility of conducting a definitive study to
evaluate the clinical effectiveness and cost-effectiveness of FJIs compared with a sham procedure in
patients with non-specific LBP of > 3 months’ duration.
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FIGURE 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram for the
systematic review search. Adapted from Moher et al.13 © 2009 Moher et al. This is an open-access article distributed
under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original author and source are credited.
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TABLE 1 Randomised controlled trials of the efficacy of therapeutic FJIs identified in previous systematic reviews
First author,
year (country,
n randomised) Population Intervention Comparator Primary outcome
Follow-up
(months) Key findings
Lilius, 198926
(Finland,
n = 109)
Unilateral LBP for > 3 months,
failed analgesics and
physiotherapy, no diagnostic
blocks
(1) Radiologically guided
intra-articular lumbar FJIs
with bupivacaine and
methylprednisolone;
(2) radiologically guided
pericapsular injections with
bupivacaine and
methylprednisolone
Sham (radiologically
guided intra-articular
lumbar FJIs with
physiological saline)
Not stated – assessed
pain, disability and
return to work
3 months No difference in outcomes at
follow-up between the two
active groups and the sham
group. Improvement in pain,
disability and work
attendance in all groups
Carette, 199127
(Canada,
n = 101)
LBP for > 6 months, normal
neurological examination,
> 50% pain reduction
after single intra-articular
diagnostic injection with
lidocaine
Fluoroscopy-guided
intra-articular lumbar FJIs
with methylprednisolone
and isotonic saline
Sham (fluoroscopy-guided
intra-articular lumbar FJIs
with isotonic saline)
Not stated – assessed
pain severity, back
mobility and limitation
of function
6 months No differences in outcomes at
1 and 3 months between the
two groups. At 6 months,
patients in the intervention
group reported greater
self-rated improvement,
lower pain intensity and less
physical disability than
patients in the sham group
Marks, 199228
(Scotland, UK,
n = 86)
LBP for > 6 months, failed
non-narcotic analgesics
and physiotherapy, no
diagnostic blocks
Radiologically guided
intra-articular lumbar FJIs
with lidocaine and
methylprednisolone
Radiologically guided
lumbar facet-joint medial
branch nerve blocks with
lidocaine and
methylprednisolone
Pain intensity 3 months Marginally longer duration of
response in the intervention
group after 1 month,
otherwise no difference in
outcomes at other time
points between the two
groups. Some short-term pain
relief seen in both groups
Revel, 199829
(France, n= 80)
LBP for > 3 months, failed
analgesics and physical
therapy, no diagnostic
blocks
Fluoroscopy-guided intra-
articular lumbar FJIs with
lidocaine plus periarticular
corticosteroid steroid
injection (not evaluated)
Fluoroscopy-guided intra-
articular lumbar FJIs with
saline plus periarticular
corticosteroid steroid
injection (not evaluated)
Pain intensity using VAS 30 minutes after
injections
Significantly reduced pain
scores in the intervention
group compared with the
comparator group
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First author,
year (country,
n randomised) Population Intervention Comparator Primary outcome
Follow-up
(months) Key findings
Manchikanti,
200130 (USA,
n = 84)
LBP for > 6 months, failed
conservative management,
positive response following
controlled comparative
diagnostic blocks with
lidocaine and bupivacaine
Lumbar facet medial branch
nerve blocks with lidocaine
or bupivacaine, Sarapin®
(High Chemical Company,
Levittown, PA, USA) and
methylprednisolone
Lumbar facet medial
branch nerve blocks with
lidocaine or bupivacaine
and Sarapin
Not stated – assessed
pain characteristics,
physical health, mental
health, functional status,
return to work and
narcotic intake
Up to 2.5 years No difference in outcomes
at follow-up between the
groups; improvement in pain
and functional outcomes in
groups I (IA and IB) and II
(IIA and IIB)
Mayer, 200431
(USA, n = 70)
‘Chronic disabling work
related lumbar spinal
disorder’ for > 6–12 months,
‘lumbar segmental rigidity’
on clinical examination, no
diagnostic blocks
Fluoroscopy-guided
bilateral intra-articular
lumbar FJIs with lidocaine,
bupivacaine and depot
corticosteroid and home
stretching exercise
programme
Home stretching exercise
programme only
Range of motion, pain
and disability
Not specified –
after completing
the home
stretching
exercise
programme
No difference in pain and
disability reported at follow-up
between the two groups, but
greater improvement in range
of motion in the intervention
group
Fuchs, 200532
(Germany,
n = 60)
LBP for > 3 months,
facet-joint osteoarthritis on
imaging
Computerised
tomography-guided
intra-articular lumbar FJIs
with triamcinolone
Computerised
tomography-guided
intra-articular FJIs with
sodium hyaluronate
Pain intensity,
functioning and quality
of life
180 days No difference in outcomes at
follow-up between the two
active groups; improvement
in pain and functional
outcomes in both groups
Manchikanti,
200833 (USA,
n = 120)
LBP for > 6 months, failed
conservative management,
80% pain relief following
controlled comparative
diagnostic blocks with
lidocaine and bupivacaine
IA: lumbar facet-joint
medial branch nerve
blocks with bupivacaine;
IB: lumbar facet-joint
medial branch nerve
blocks with bupivacaine
and Sarapin
IIA: lumbar facet-joint
medial branch nerve
blocks with bupivacaine
and steroid; and IIB:
lumbar facet-joint medial
branch nerve blocks with
bupivacaine, steroid and
Sarapin
Not stated – assessed
pain relief, work status,
opioid intake and
functional status
1 year No difference in outcomes
at follow-up between the
groups; improvement in pain
and functional outcomes in
both groups
Kawu, 201134
(Nigeria, n= 18)
LBP for > 3 months, failed
analgesics, MRI features of
facet-joint arthropathy, no
diagnostic blocks
Radiologically guided
lumbar FJIs with
bupivacaine and
methylprednisolone
Physiotherapy (McKenzie
regimen)
Not stated – assessed
pain relief and
satisfaction with
treatment
6 months Greater decreases in pain and
higher levels of satisfaction in
the intervention group than
in the comparator group
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TABLE 1 Randomised controlled trials of the efficacy of therapeutic FJIs identified in previous systematic reviews (continued )
First author,
year (country,
n randomised) Population Intervention Comparator Primary outcome
Follow-up
(months) Key findings
Celik, 201135
(Turkey, n= 80)
LBP for < 4 months, no
diagnostic blocks
Fluoroscopy-guided lumbar
FJIs with bupivacaine and
methylprednisolone
Diclofenac,
thiocolchicoside and bed
rest for 4 days
Not stated – assessed
LBP disability and pain
intensity
6 months Greater decreases in pain and
disability in the intervention
group than in the comparator
group; improvement in pain
and functional outcomes in
both groups
Yun, 201236
(Korea, n = 57)
LBP (no duration specified),
clinical indicators of facet
syndrome, no diagnostic
blocks
Fluoroscopy-guided lumbar
FJIs with lidocaine and
triamcinolone
Ultrasound-guided lumbar
FJIs with lidocaine and
triamcinolone
Pain and activities of
daily living
3 months No difference in outcomes at
follow-up between the two
active groups; improvement
in pain and functional
outcomes in both groups
Ribeiro, 201337
(Brazil, n= 60)
LBP for > 3 months, clinical
diagnosis of lumbar facet-
joint syndrome, no
diagnostic blocks
Fluoroscopy-guided
intra-articular lumbar FJIs
with lidocaine and
triamcinolone
Intramuscular
paravertebral injections
with lidocaine and
triamcinolone
Not stated – assessed
quality of life, functional
capacity, pain on back
extension, percentage
improvement scale,
analgesic usage
24 weeks ‘Slightly superior’ results in
the intervention group than
in the comparator group;
improvement in pain and
functional outcomes in both
groups
Lakemeier,
201338
(Germany,
n = 56)
LBP for > 24 months,
> 50% pain reduction after
single intra-articular
diagnostic injection with
bupivacaine
Fluoroscopy-guided
intra-articular lumbar FJIs
with bupivacaine and
betamethasone
Radiofrequency
denervation of the lumbar
facet-joint medial branch
nerves
LBP-related disability
using the Rowland
Morris Disability
Questionnaire
6 months No difference in outcomes at
follow-up between the two
active groups; improvement
in pain and functional
outcomes in both groups
MRI, magnetic resonance imaging; VAS, visual analogue scale.
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6
To inform a full trial, a number of questions first need to be assessed by a feasibility study:
1. Given the multiple sites with the potential to generate back pain, can patient selection criteria be
optimised, using clinical and investigative diagnostic methods?
2. Can the method of injection be standardised and an appropriate sham procedure be established?
3. Can justification for further studies to evaluate treatment methods to target and attenuate the source
of chronic LBP of facet-joint origin be delivered?
4. Is a sham-controlled trial design acceptable to patients and clinicians?
5. Can a sufficient number of patients be recruited and retained?
Study objectives
l To assess the eligibility criteria and recruitment and retention of patients in the two treatment arms
(FJIs vs. sham procedure) by assessing the feasibility of recruitment in the three centres, reviewing the
number of completed patient data sets, auditing the quality of data entry at the centres and assessing
and analysing any protocol violations (such as failure to deliver the CPP programme – recommended
therapy at the time of the establishing this study39), side effects and other adverse outcomes.
l To assess the feasibility and acceptability of the two treatment arms from the point of view of patients
and their pain teams.
l To assess the feasibility of the proposed definitive study design, including:
¢ testing of the randomisation and blinding procedures
¢ development of appropriate active and sham procedures for FJIs
¢ assessment of the consistency of the trial sites in terms of delivering the CPP programme
¢ assessment of the ability to collect the outcomes proposed for the main trial (pain, functioning,
health-related quality of life, anxiety and depression, health-care resource utilisation, complications
and adverse events).
l To estimate outcome standard deviations (SDs) to inform the power calculation for a definitive study.
l To finalise the protocol design, statistical plan, number of centres required and study duration for the
definitive study.
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Chapter 2 Methods
Study design
This feasibility study utilised a blinded parallel two-arm pilot randomised controlled trial design. Following
a positive diagnostic medial branch nerve block, participants with non-specific LBP were individually
randomised in a 1 : 1 ratio to receive either the FJI (intervention group) or a sham (placebo injection)
procedure (control group). Both the intervention group and the control group received a CPP programme
after their active or sham injections.
Participants
The study sought patients with non-specific LBP based on the following inclusion and exclusion criteria.
Inclusion criteria
l Patients aged 18–70 years attending pain clinics identified during routine clinical assessment of
non-specific LBP. Clinical indicators of pain of facet-joint origin included tenderness over the facet-joints,
referred leg pain above the knees and worsening pain on extension, flexion and rotation of the
lumbar spine.
l Low back pain of ≥ 3 months’ duration.
l An average pain intensity score of ≥ 4 out of 10 in the 7 days preceding recruitment despite
NICE-recommended treatment. NICE clinical guideline CG887 recommended providing patients with
advice and information to promote self-management of their LBP and offering one of the following
treatments, taking into account patient preference: an exercise programme, a course of manual
therapy or a course of acupuncture.
l Dominantly paraspinal (not midline) tenderness at two bilateral lumbar levels.
l At least two components of NICE-recommended best non-invasive care completed, including education
and one of a physical exercise programme, acupuncture or manual therapy.7
l Patients are suitable for the FJIs.
Exclusion criteria
l Patient refusal to consent.
l More than four painful lumbar facet-joints. No more than four facet-joints were to be injected to limit
the total dose of intra-articular steroids.
l Patient has not completed at least two components of NICE-recommended best non-invasive care,
including education and one of a physical exercise programme, acupuncture or manual therapy.7
l ‘Red flag’ signs. These are possible indicators of serious spinal pathology and include thoracic pain,
fever, unexplained weight loss, bladder or bowel dysfunction, progressive neurological deficit and
saddle anaesthesia.40
l Known hypersensitivity to study medications.
l Dominantly midline tenderness over the lumbar spine, any other dominant pain or radicular pain.
l Any major systemic disease or mental health illness that may affect the patient’s pain, disability and/or
their ability to exercise and rehabilitate, as judged by the Principal Investigators.
l Any active neoplastic disease, including primary or secondary neoplasm.
l Pregnant or breastfeeding patients (verbal confirmation obtained at screening; prior to each
interventional procedure involving radiography, local hospital procedures will be followed to confirm
that female participants are not pregnant).
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l Any evidence of previous lumbar FJIs, previous lumbar spinal surgery or any major trauma or infection
to the lumbar spine.
l Patients with morbid obesity (body mass index of ≥ 35 kg/m2).
l Participation in another clinical trial of an investigational medicinal product or disease-related
intervention in the past 30 days.
l Patients unable to commit to the 6-month study duration.
l Patients involved in legal actions or employment or benefit tribunals related to their LBP.
l Patients with a known history of substance abuse.
Recruitment procedures
It was originally planned to recruit patients from pain clinics at the three participating NHS centres and
their associated community based pain clinics. However, because of the early termination of the study by
the funder, recruitment was undertaken at only one centre, Barts Health NHS Trust. Recruitment took
place over 9 months. The first participant was recruited in January 2016 and the last participant was
recruited in September 2016.
Patients were referred by their general practitioner (GP) as a standard clinical referral with LBP requiring
further specialist assessment, for reasons such as uncertain diagnosis, failure of conservative treatment and
expectation of therapeutic interventions. Potentially eligible patients were identified by a pain clinician
based on the inclusion and exclusion criteria.
Participants were free to withdraw from the study at any time without giving a reason; the participant
information sheet stated that ‘a decision to withdraw from the study at any time will not affect the
standard of care that you receive now or in the future’ (see Appendix 5). Participants who withdrew from
the study received a routine follow-up appointment in their pain clinic for continuing assessment and
management by their pain physician.
Informed consent
Potential participants were given a copy of the information sheet (see Appendix 5) and a verbal
explanation of its contents, including information on the nature of the study, the implications and
constraints of the study protocol and any known side effects and risks involved in taking part in the study.
A medically qualified investigator on the delegation log obtained written informed consent.
Sample size calculation
At the outset of the study it was expected that a total of 60 patients would be recruited, to be able to
estimate the precision of an assumed 20% attrition rate with an error of ±5% at the 95% confidence
level. Assuming that 24 full data sets per arm were completed at the end of the study, this would give a
reasonable estimate of variance of the outcomes.41
Diagnostic test
Following screening and consent, all participants underwent a diagnostic medial branch nerve block. Those
who achieved a positive response were randomised to the intervention group or the control (sham) group.
The diagnostic medial branch nerve injections were carried out at each painful lumbar level under
radiological guidance. With the patient lying in the prone position on a radiolucent table, the investigator
METHODS
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examined the patient’s back to elicit paraspinal tenderness and confirmed appropriate landmarks and
facet-joints to be injected using radiological image intensification. The C-arm of the image intensifier was
obliquely rotated as required to facilitate visualisation of the target for injection. The spinal needle was
used to inject 0.5 ml of 1% lidocaine per level, with six levels injected. A positive response was defined as
a ≥ 50% pain reduction lasting for > 30 minutes, that is, the duration of action of lidocaine, measured
using a pain intensity numerical rating scale (NRS) and assessed in the standing position.
Interventions
The FJIs, sham procedure and diagnostic tests were carried out by the Principal Investigator at Barts Health
NHS Trust, a Fellow of the Faculty of Pain Medicine of the Royal College of Anaesthetists in the UK. During
all of the interventional procedures strict aseptic conditions were adhered to and local theatre protocols were
followed with regard to admission and discharge criteria, including the use of the World Health Organization
(WHO) Surgical Safety Checklist42 to identify the correct patient prior to starting the procedure. The
investigator carrying out the injections was not blinded to randomisation group.
Active injection
Before undertaking this feasibility study, a web-based survey of 250 UK pain specialists was carried out
utilising the Delphi method to agree on the choice of needle, injectate and volume of injection, as well as
the choice of steroid, dose and volume and maximum dose of steroid (see Appendix 6).
In the intervention group, each participant received four FJIs at two bilateral lumbar levels, with 0.5 ml of
0.5% bupivacaine (Marcain Polyamp Steripack 0.5%, Aspen Pharma Trading Limited, Dublin, Ireland) and
20 mg of methylprednisolone (Depo-Medrone 40 mg/ml, Pfizer, Kent, UK) injected per joint. No more
than four facet-joints were to be injected to avoid any potential confounding effect attributable to the
systematic action of exceeding 80 mg of methylprednisolone. The volume of injectate did not exceed 1 ml
per joint as it would be possible to rupture the intra-articular capsule with greater volumes, spreading the
local anaesthetic and steroid to other potentially pain-generating structures.
Paraspinal tenderness was elicited as described previously. The skin was anaesthetised with 1% lidocaine
(Lidocaine Hydrochloride Injection BP 1% w/v, Hameln Pharmaceuticals Ltd, Gloucester, UK) and a 22G 90-mm
Quincke spinal needle was advanced through the skin, subcutaneous tissue and paraspinal muscle towards
the facet-joint under radiological guidance. Entry of the needle was confirmed by visualisation of the needle
position within the joint space and local anaesthetic and steroid were injected into the joint.
Sham procedure
The control group received four injections of 0.5 ml of normal saline (0.9% sodium chloride) at two
bilateral lumbar levels. A low volume was chosen to avoid irritation of any structure that is part of the
facet-joints, including the fibrous capsule, synovial membrane, hyaline cartilage and bone. The sham group
would not receive systematic steroid administration as it has been shown that the addition of parenteral
steroid does not contribute to the pain relief achieved by targeted injections.43
Paraspinal tenderness was elicited as described previously. The skin was anaesthetised with 1% lidocaine
and a 22G 90-mm Quincke spinal needle was advanced through the skin, subcutaneous tissue and
paraspinal muscle towards the periarticular space under radiological guidance. Placement of the needle in
the periarticular space was confirmed by visualisation of the needle position next to the joint space and
normal saline was injected at this site.
Combined physical and psychological programme
Both the intervention group and the control group underwent a CPP programme delivered by trained
physiotherapists. Research on CPP management of LBP has demonstrated that equally effective
management can be achieved with far fewer than the 100 hours prescribed in the 2009 NICE guidance.7
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The study therefore proposed to deliver a programme drawing on the methods and evidence from the
Back Skills Training (BeST) trial.44
Physiotherapists on the delegation log were trained to deliver the Back Skills Training programme by the
lead physiotherapist. Individual physiotherapists undertook approximately 10 hours of online training at
www.backskillstraining.co.uk (accessed 11 November 2017) and received a certificate of completion and
a trainer manual to support CPP programme delivery. The lead physiotherapist organised face-to-face
meetings with each physiotherapist to ensure competency and standardised delivery.
Each participant attended an initial one-to-one hour-long assessment with a trained physiotherapist at
which information was gathered, including the impact of pain on their activity and their thoughts and
beliefs regarding LBP. Individualised goals were identified with one specific to physical activity. Participants
then selected and practised an individualised exercise programme.
Six weekly 1.5-hour sessions of a group-based CPP programme were scheduled for each participant.
Completion of the CPP programme was defined as having completed a minimum of four out of six sessions.
The session contents are detailed on the website www.backskillstraining.co.uk and address the following:
l understanding pain
l pain fluctuations
l unhelpful thoughts and feelings
l restarting activities or hobbies
l when pain worries us
l coping with flare-ups.
One session per programme was observed by the lead physiotherapist to assess consistency of delivery
and to provide feedback and support for the physiotherapists running the course. Two research
physiotherapists in total, including the lead physiotherapist, delivered the programme to the study
participants at Barts Health NHS Trust.
Each participant received a Back Skills Training Patient Workbook, which provided a summary of each
week’s content for their reference at home. It was expected that participants would be in groups of fewer
than 10 people; four to five groups of four to five participants per site were anticipated.
Regulatory approvals
The study was conducted in compliance with the principles of the Declaration of Helsinki (1996)45 and the
principles of Good Clinical Practice46 and in accord with all applicable regulatory requirements including
but not limited to the Research Governance Framework47 and the Medicines for Human Use (Clinical Trials)
Regulations 2004,48 as amended in 2006 and 2008, the sponsor’s policies and procedures and any
subsequent amendments.
The required regulatory approvals were obtained in the UK. The study received ethics approval from the
National Research Ethics Service (NRES) Committee London – City & East (reference 15/LO/0500) and
clinical trial authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA)
(reference 14620/0046/001–0001). The trial protocol was reviewed by the MHRA’s clinical trials team and
the trial was considered to be a type A Clinical Trial of an Investigational Medicinal Product (CTIMP), that
is, the risks are no higher than those of standard medical care. The Summary of Product Characteristics
(SmPCs) for each investigational medical product (bupivacaine and methylprednisolone acetate) are
available to view on the Electronic Medicines Compendium.49,50 Health Research Authority (HRA) approval
was obtained and the study was given permission by the sponsor’s Joint Research Management Office
(JRMO) to recruit patients at Barts Health NHS Trust.
METHODS
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Imaging authorisation was given by the sponsor’s clinical radiation expert and medical physics expert, as all
of the participants would receive ionising radiation in the form of X-rays for the diagnostic injections, FJIs
and sham procedure.
Randomisation and blinding
Participants were allocated to either the intervention group or the control group in a 1 : 1 ratio, with
stratification by centre and minimisation on baseline pain scores (categories). To ensure concealment, the
allocation sequence was computer generated and provided through a password-protected web-based
portal developed and maintained by the Peninsula Clinical Trials Unit (PenCTU).
It was not possible to blind the operator (Principal Investigator) as the injections were intentionally given at
different sites (intra-articular vs. periarticular) and the injections looked different (methylprednisolone is
provided as a cloudy suspension, whereas the sham injection was clear). However, study participants and
the remainder of the research team, including the Chief Investigator, research nurses conducting the
outcome assessments and data analysts, were blinded for the duration of the study. Unblinding took place
at the end of the study once data analysis had been completed. A standard operating procedure was in
place for emergency unblinding, in accordance with the sponsor guidelines.
Outcomes
The outcome questionnaire visits took place in research nurse-led clinics at baseline (pre randomisation)
and at 6 weeks, 3 months and 6 months post randomisation. A sample case report form is shown in
Appendix 7 and the schedule of outcome assessment is shown in Table 2. The outcome questionnaire
covered a range of pain- and disability-related issues and was in accord with the Initiative on Methods,
Measurement, and Pain Assessment in Clinical Trials (IMMPACT)-recommended core outcome measures
for chronic pain trials.51 The following assessment tools were used in the study.
l Pain intensity and characteristics – Brief Pain Inventory (BPI) (Short Form) Modified,52 with its 11-point
NRS, and short-form McGill Pain Questionnaire version 2 (SF-MPQ-2).53 As movement could potentially
influence the intervention (lumbar FJIs or sham procedure), all numerical rating scores were assessed in
the standing position.
l Use of co-analgesics in the previous week – participant self-report.
l Lack of efficacy of pain relief, or, for side effects, early withdrawal from the study.
l Expectation of benefit (asked at baseline only) – measured on a scale from 0 to 6, ranging from ‘expect
no improvement’ to ‘expect total improvement’.
l Health-related quality of life – EuroQol-5 Dimensions five-level version (EQ-5D-5L)54 and Short Form
questionnaire-12 items (SF-12).55
l Functional impairment – Oswestry Low Back Pain Disability Questionnaire56 and Pain Self-Efficacy
Questionnaire (PSEQ).57
l Satisfaction with treatment (after treatment given) – NRS from 0 to 10, with 0 = ‘extremely dissatisfied’
and 10 = ‘extremely satisfied’.
l Complications and adverse events – these were the subject of enquiry at visits and following
procedures, as well as being spontaneously reported at any time. They were acted on as necessary and
for the patients’ benefit and were fully documented on case report forms and medical notes.
l Co-psychological well-being – Hospital Anxiety and Depression Scale (HADS),58 Pain Catastrophizing
Scale (PCS),59 SF-12 and BPI.
l Health-care utilisation and costs and impact on productivity –Stanford Presenteeism Scale (SPS) 6,60
self-reported measures of sickness absence over the previous 3 months and health-care utilisation in
the form of hospital visits, treatments and medications. These data were collected at each outcome visit
on the case report form.
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Adverse events
Adverse events were assessed by a blinded subinvestigator at each visit and an adverse event form was
completed as necessary (see Appendix 8). Adverse events are defined as any untoward medical occurrence
in a subject to whom a medicinal product has been administered; an adverse reaction is an untoward and
unintended response in a subject to an investigational medicinal product (IMP) that is related to any dose
administered to that subject. A serious adverse event or reaction results in death, is life-threatening,
requires inpatient hospitalisation or prolongation of an existing hospitalisation, results in persistent or
significant disability or incapacity or is a congenital anomaly or birth defect. A suspected unexpected
serious adverse reaction is any serious adverse event that is both suspected to be related to the IMP
and unexpected.
TABLE 2 Schedule of assessments
Assessment Prescreening
Visit
1 2 3
4 (6 weeks
after
injections
± 2 weeks)
5 (3 months
after
injections
± 2 weeks)
6 (6 months
after
injections
± 2 weeks)
Informed consent ✗
Targeted physical
examination
✗ ✗
Inclusion/exclusion criteria
fulfilled
✗ ✗ ✗ ✗ ✗ ✗
Medical history recorded ✗
Demographic data
recorded
✗
Drug history recorded ✗ ✗ ✗ ✗ ✗ ✗
Breakthrough analgesia
recorded
✗ ✗ ✗ ✗
Adverse events ✗ ✗ ✗ ✗ ✗
Outcome questionnaires ✗ ✗ ✗ ✗
Expectation of benefit
scale
✗
BPI (Short Form) ✗ ✗ ✗ ✗
SF-MPQ-2 ✗ ✗ ✗ ✗
EQ-5D-5L ✗ ✗ ✗ ✗
SF-12 ✗ ✗ ✗ ✗
Oswestry Low Back Pain
Disability Questionnaire
✗ ✗ ✗ ✗
PSEQ ✗ ✗ ✗ ✗
HADS ✗ ✗ ✗ ✗
Pain Catastrophizing
Scale
✗ ✗ ✗ ✗
SPS 6 ✗ ✗ ✗ ✗
Satisfaction with
treatment scale
✗ ✗ ✗
METHODS
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Adverse events not already identified locally were recorded at each trial visit and managed in accordance
with the sponsor’s requirements. Serious adverse events were reported to the JRMO by the investigators
within 24 hours of the research team becoming aware of them and causality and expectedness were
confirmed by the Chief Investigator, as the sponsor’s medical representative.
Study management and committees
The Trial Management Group (TMG) was responsible for the overall management of the project and
included all co-applicants and members of the study research team. A Trial Steering Committee (TSC)
provided independent advice and support to the study and aimed to report to the funder on study
progress. It was chaired by an independent clinician with experience of pain trials. A Data Monitoring
Committee (DMC) had access to unblinded data and made recommendations to the TSC on whether there
were any ethical or safety reasons why the trial should not continue. It included independent members
who were all experts in pain medicine.
Patient and public involvement
Patients with personal experience of LBP collaborated in the early stages of study design, for example
advising on the acceptability of study visits and the outcome questionnaires. The questionnaires were
tested on patients presenting to the multidisciplinary pain clinics and were deemed to be acceptable.
Patient representatives were invited to attend the TSC meetings; however, there was no patient or public
involvement in the management or running of the trial beyond the initial set-up stage.
Statistical analysis
Analyses were conducted in accordance with the International Conference on Harmonisation (ICH)
statistical guidelines for clinical trials61 and the Consolidated Standards for Reporting Trials (CONSORT)
reporting checklist for trials.62 As this was a feasibility study, it was not planned to formally inferentially test
differences in outcomes or costs between or within the groups. Mean recruitment and attrition rates were
calculated with 95% confidence intervals (CIs). Means and SDs for all outcomes for the two groups at
baseline and at the follow-up visits were reported. A detailed statistical analysis plan was prepared by the
study statistician (RST) prior to any data analysis. Analyses were performed blinded to group allocation
using Stata® 14.2 (StataCorp LP, College Station, TX, USA).
Health economics analysis
A health economics analysis plan was developed in collaboration with the study’s health economist and
statistician. A formal economic analysis was not proposed (as this was a feasibility study). Any outcomes
from this feasibility study would be used in the design of the definitive study. In particular, the health
economics analysis looked at the ability to collect the outcomes proposed for the main trial and to inform
a robust framework to assess the cost-effectiveness of lumbar FJIs for persistent non-specific LBP for a
future definitive randomised controlled trial.
The resources used in the delivery of the intervention and sham procedure were calculated from the case
report forms and in consultation with the trial team. Health-care resource use was captured through
administration of specific questions to trial participants at each assessment, with responses recorded on
case report forms, with a focus on collecting data on the most relevant and important drivers of health
resource use and costs. Published national costs were used to calculate the costs of delivering each
treatment arm. A summary of the costing methods employed are presented in Appendix 9. In addition,
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a literature review was conducted to review the scope and quality of the current economic evidence base
for the use of FJIs in patients with non-specific LBP (see Appendix 9).
Descriptive analyses of the outcomes were used to report utilities based on the relevant tariff for each
of the health-related quality-of-life outcomes. Economic outcomes were measured using the EQ-5D-5L
(the preferred approach of the study team and for NICE decision-making) and the Short Form questionnaire-6
Dimensions (SF-6D63), used as a means of calculating utilities from the SF-12. A descriptive analysis of the
health-related quality of life outcomes was summarised and was to provide estimates of quality-adjusted
life-years (QALYs) gained as a result of receiving the intervention within the study period.
Summary of changes to the study protocol
The minor and major amendments made to the protocol over the duration of the study are detailed in
Appendix 10.
METHODS
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Chapter 3 Results
Screening and recruitment
It was originally planned to screen and recruit participants across three centres; however, given the delays
in study set-up, the funder directed that screening and recruitment take place at one centre only. The
timelines of the study and the reasons for the delays are presented at the end of this chapter.
Recruitment began at Barts Health NHS Trust on 20 January 2016 and was terminated on 30 September
2016. As shown in Figure 2, during this time 628 patients referred to the recruiting clinics by their GP with
non-specific LBP were screened for eligibility to enter the study. Of the 50 patients who met the inclusion
criteria, 16 agreed to take part in the study and 11 received the diagnostic test for facet-joint disease. Nine
participants had a positive response and were randomised to receive either lumbar FJIs with steroid or a
sham procedure. The target sample size in each centre was 20 participants. The actual participant
screening-to-recruitment ratio was 70 : 1 (628 : 9), which contrasts with an expected prestudy ratio of
17 : 1 (1000 : 60). The recruitment rate varied between zero and four patients per month (median two
participants per month (Table 3).
The reasons for screening failure are detailed in Table 4. The greatest proportion of patients was screened
from the pain clinics at St Bartholomew’s Hospital, with a screened/recruited fraction of 1.69% (Table 5).
Although only 16 patients were screened from the community pain clinic at the Essex Lodge GP surgery in
Plaistow, East London, the screened/recruited fraction was higher at 12.5%. No participants were recruited
from the spinal orthopaedic clinic at The Royal London Hospital or from the pain clinics at Whipps Cross
University Hospital and Mile End Hospital.
Nine out of the 11 enrolled participants had a positive response to the diagnostic lumbar facet medial
branch nerve block (82%, 95% CI 48% to 98%).
Adherence to allocated treatment
Facet-joint active and placebo injection
All the participants received their randomised procedure as planned and no problems with the injections
were reported. None of the participants received any additional interventional pain procedures during their
time in the study.
Combined physical and psychological programme
All nine participants were invited to attend a CPP programme after they had received their randomised
procedure. Three physiotherapy-led CPP programmes took place between study months 12 and 20, with
four participants in the first group, three in the second group and two in the final group. Six of the nine
(67%) participants successfully completed the CPP programme, defined in the protocol as having attended
at least four out of the six sessions. The median number of CPP programme sessions attended was four.
One participant attended the initial CPP programme assessment but did not attend the programme because
of illness during that period and another participant was unable to attend the CPP programme for personal
reasons. A third participant did not attend the CPP programme because of unplanned overseas leave.
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TABLE 3 Screening and recruitment by month
Outcome
Recruiting month
Total1 2 3 4 5 6 7 8 9
Recruited 1 4 2 0 2 2 0 2 3 16
Screened 8 26 6 37 18 46 78 209 200 628
Patients with non-specific low back pain
(n = 628)
Eligible to enter study
(n = 50)
Patients screened and consented
(n = 16)
Diagnostic test for facet-joint disease
(n = 11)
Six medial branch nerve blocks through a spinal needle using 0.5 ml
of 1% lidocaine per injection, under fluoroscopic guidance
Positive diagnostic test
(82%, n = 9)
50% or greater pain reduction lasting > 30 minutes
Baseline outcome assessments
Randomisation
Combined physical and psychological
programme and facet-joint injections
(n = 5)
Four intra-articular facet-joint injections
through a spinal needle at two bilateral lumbar
levels, using 0.5 ml of 0.5% bupivacaine and 
20 mg of methylprednisolone per joint, under
fluoroscopic guidance
Combined physical and psychological
programme and sham procedure
(n = 4)
Four peri-articular injections through a
spinal needle at two bilateral lumbar levels,
using 0.5 ml of normal saline per injection,
under fluoroscopic guidance
Outcome assessments at 6 weeks, 3 months and 6 months
(n = 8)
Drop-out
(n = 1)
Drop-out
(n = 5)
Negative diagnostic test
(n = 2)
Declined to consent
(n = 34)
Not eligible
(n = 578)
• Previous lumbar 
   facet-joint injections 
   or spinal surgery
• Other dominant pain
   or widespread pain
• Radicular pain
• Pain of ≥ 3 months’ duration
• Pain of ≥ 4/10 in the 7 preceding days
• Signs and symptoms of facet-joint disease, including bilateral localised
   paraspinal tenderness at two lumbar levels
• Received two or more components of NICE-defined best non-invasive
   care (education and one of physical exercise programme, acupuncture 
   or manual therapy)
FIGURE 2 Consolidated Standards for Reporting Trials (CONSORT) flow diagram showing the flow of participants
through the trial.
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TABLE 4 Reasons for screening failure
Reasons Number of patients
Previous lumbar FJIs 192
Previous lumbar FJIs 163
Previous lumbar FJIs and no previous physiotherapy 3
Previous lumbar FJIs and radiofrequency denervation 18
Previous lumbar FJIs or radiofrequency denervation and aged > 70 years 8
Other dominant pain or widespread pain 92
Radicular pain 64
Aged > 70 yearsa 42
Aged > 70 years 29
Previous lumbar FJIs or radiofrequency denervation and aged > 70 years 8
Aged > 70 years and has radicular pain 12
Aged > 70 years and has widespread pain 1
Other reasons for not meeting inclusion/exclusion criteria 36
Did not wish to take part 34
Previous major trauma to the lumbar spine 29
‘Red flag’ signs 29
Previous lumbar spinal surgery 25
Study team unable to contact 17
Already taking part in another study 12
Limited or no English language 11
Active neoplastic disease 7
No previous physiotherapy 7
Morbid obesity (body mass index of ≥ 35 kg/m2) 7
Learning difficulties or known mental health illness 5
Known history of substance abuse 2
Aged < 18 years 1
a Some participants were in more than one category.
TABLE 5 Location of screening clinics at Barts Health NHS Trust
Clinic location
Number of patients
Screened/recruited
fraction (%)Screened for eligibility Randomised
Pain clinic, St Bartholomew’s Hospital 413 7 1.69
Spinal orthopaedic (‘fracture’) clinic, The Royal
London Hospital
180 0 0
Community pain clinic, Essex Lodge GP surgery 16 2 12.5
Pain clinic, Whipps Cross Hospital 12 0 0
Tower Hamlets Persistent Pain Services, Mile End
Hospital
7 0 0
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Study dropout and attrition
Of the 16 patients recruited and who consented to take part in the study, five withdrew before they
received their diagnostic injections (although all completed the baseline assessment questionnaires). One
patient already had lumbar FJIs booked for a future date and two changed their mind about taking part
(one for personal reasons and one for family reasons). Two were unable to attend for the injections as the
study dates were not suitable for them.
Of the nine participants who were randomised, eight completed the study (defined as having completed
the final set of questionnaires 6 months after the randomised procedure), resulting in an 11% (95% CI
0.2% to 48%) attrition rate. The expected attrition rate was 20%. Six study deviations were recorded:
three participants did not complete the CPP programme and three participants did not complete all of the
questionnaire sets (Figure 3). A ‘study deviation’ was defined as a participant who did not attend a study
visit or CPP programme session but who did not drop out of the study completely.
Completed CPP
(n = 4)
Study
deviation
(n = 1)
(a)
Combined physical and psychological
programme and facet-joint injections
(n = 5)
Four intra-articular facet-joint injections
through a spinal needle at two bilateral 
lumbar levels, using 0.5 ml of 0.5% bupivacaine
 and 20 mg of methylprednisolone per joint, 
under fluoroscopic guidance
Study
deviation
(n = 1)
Outcome
assessments
at 6 weeks
(n = 5)
Outcome
assessments
at 3 months
(n = 4)
Outcome
assessments
at 6 months
(n = 5)
FIGURE 3 Flow diagram showing the study deviations and dropouts during the study. (a) Combined physical and
psychological programme and facet-joint injections; and (b) combined physical and psychological programme and
sham procedure. (continued )
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There were low levels of missingness of within-questionnaire data, as shown in Appendix 11. This is
summarised in Table 6.
Baseline characteristics and outcomes
The mean age of eligible participants was 45 years, with a similar proportion of males and females. Six out
of 14 participants (43%) were not working at baseline (Table 7).
(b)
Completed CPP
(n = 2)
Study
deviation
(n = 2)
Combined physical and psychological
programme and sham procedure
(n = 4)
Four peri-articular injections through a
spinal needle at two bilateral lumbar levels,
using 0.5 ml of normal saline per injection,
under fluoroscopic guidance
Study
deviation
(n = 1)
Drop-out
(n = 1)
Study
deviation
(n = 2)
Outcome
assessments
at 6 weeks
(n = 2)
Outcome
assessments
at 3 months
(n = 3)
Outcome
assessments
at 6 months
(n = 3)
FIGURE 3 Flow diagram showing the study deviations and dropouts during the study. (a) Combined physical and
psychological programme and facet-joint injections; and (b) combined physical and psychological programme and
sham procedure.
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TABLE 6 Data missingness, CPP programme attendance and allocation groups
Participant
number
Questionnaires completed Number of CPP
programme
sessions attended
CPP
programme
group
Randomisation
groupBaseline 6 weeks 3 months 6 months
1 Y Y Y Y 5 1 Intervention
2 Y N N Y 0 1 Sham
3 Y Y Y Y 6 1 Sham
4 Y Y Y Y 4 1 Intervention
5 Y Y Y Y 6 2 Sham
6 Y Y N Y 0 2 Intervention
7 Y Y Y Y 5 2 Intervention
8 Y Y Y N 0 3 Sham
9 Y Y Y Y 4 3 Intervention
N, no; y, yes.
TABLE 7 Participant characteristics for all eligible and randomised participants
Characteristic
All eligible
(N= 16a)
Not randomised
(N= 7)
Randomisation group
Sham (N= 4)
Intervention
(N= 5)
Age (years), mean (SD) 44.8 (13.2) 44.4 (14.3) 50.5 (14.4) 40.8 (11.5)
Sex (male), n (%) 9 (56) 2 (29) 2 (50) 3 (60)
BMI (kg/m2), mean (SD) 27.0 (5.1) 29.9 (5.1) 29.6 (4.7) 27.7 (5.6)
Baseline pain (0–10 VAS), mean (SD) 8.5 (1.5) 8.0 (1.7) 9.5 (1.0) 8.4 (1.5)
Duration of pain (months), mean (SD) 71.9 (88.7) 46.0 (53.6) 51.0 (46.3) 124.8 (135.9)
Location of pain, n (%)
Bilateral 12 (75) 5 (71) 3 (75) 4 (80)
Unilateral 4 (25) 2 (29) 1 (25) 1 (20)
Aware of pain (years), mean (SD) 6.8 (7.6) 5.2 (4.6) 4.2 (3.9) 10.4 (11.3)
Description of health, n (%)
Excellent 0 (0) 0 (0) 0 (0) 0 (0)
Very good 1 (7) 0 (0) 0 (0) 0 (0)
Good 9 (64) 3 (60) 3 (75) 1 (20)
Fair 1 (7) 1 (20) 0 (0) 3 (60)
Poor 3 (21) 1 (20) 1 (25) 1 (20)
Work status, n (%)
Full time 7 (50) 1 (17) 2 (50) 4 (80)
Part time 1 (7) 0 (0) 1 (25) 0 (0)
Not working 4 (29) 3 (50) 0 (0) 1 (20)
Other 2 (14) 2 (33) 1 (25) 0 (0)
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Baseline patient-reported outcomes indicated a population with substantial levels of pain [mean 8.5 on a
0–10 visual analogue scale (VAS)] that was predominantly bilateral (12/16, 75%) and which had a mean
duration of 72 months (see Table 7). In terms of the primary and secondary outcomes, high baseline levels
of disability and mental ill health and poor overall health-related quality of life were seen (Tables 7 and 8).
Given the small number of participants randomised, not unexpectedly there was evidence of imbalance in
participant characteristics and patient-reported outcomes between the two groups at baseline (see Table 8).
Primary and secondary outcomes at follow-up
Given the feasibility nature of the study and the small number of participants randomised, the primary and
secondary outcomes at 6 weeks’ and 3 and 6 months’ follow-up are presented descriptively, with no
inferential between or within comparisons undertaken or reported (Table 9).
Adverse events
Three study participants reported adverse events, with two serious events reported by one participant.
All three participants reported a flare-up of their LBP, which resolved (Table 10).
TABLE 7 Participant characteristics for all eligible and randomised participants (continued )
Characteristic
All eligible
(N= 16a)
Not randomised
(N= 7)
Randomisation group
Sham (N= 4)
Intervention
(N= 5)
Illness caused participant to stop working, n (%)
Yes 10 (71) 1 (20) 3 (75) 3 (60)
No 4 (29) 4 (80) 1 (25) 2 (40)
Missed work days, mean (SD) 13.5 (31.1) 0 (0) 30.0 (52.0) 4.5 (3.7)
Level of activity prior to procedure, n (%)
Hard manual 2 (29) 0 (0) 1 (33) 1 (33)
Lifting 1 (14) 1 (100) 0 (0) 0 (0)
Walking 0 (0) 0 (0) 0 (0) 0 (0)
Sedentary 4 (57) 0 (0) 2 (66) 2 (66)
Current smoker, n (%)
Yes 11 (79) 2 (40) 0 (0) 1 (20)
No 3 (21) 3 (60) 4 (100) 4 (80)
Alcohol (units per week), mean (SD) 0.7 (1.1) 0.6 (1.3) 0.5 (1.0) 1.0 (1.2)
Exercise per week, n (%)
> 5 days 2 (14) 0 (0) 1 (25) 1 (20)
3–5 days 1 (7) 1 (20) 0 (0) 0 (0)
1–2 days 5 (36) 1 (20) 1 (25) 3 (60)
< 1 day 6 (43) 3 (60) 2 (50) 1 (20)
VAS, visual analogue scale.
a Not all eligible and randomised participants contributed data.
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TABLE 8 Primary and secondary outcomes at baseline
Outcome
All eligible
(n= 16a)
Not randomised
(n= 7)
Randomisation group, mean score (SD)
Sham (n= 4)
Intervention
(n= 5)
BPI (0–10)
Worst pain 8.5 (1.7) 9.0 (0.9) 9.3 (1.5) 7.2 (2.2)
Least pain 6.0 (2.7) 6.2 (2.3) 6.0 (2.7) 6.0 (3.5)
Average pain 7.4 (1.5) 7.7 (1.5) 7.5 (1.9) 7.0 (1.6)
Pain now 6.5 (2.8) 5.2 (2.9) 8.0 (2.3) 6.8 (2.8)
Pain severity 7.1 (1.6) 7.0 (0.8) 7.7 (1.7) 6.8 (2.4)
General activity 7.7 (2.5) 7.7 (2.6) 9.3 (1.5) 6.6 (1.2)
Mood 6.9 (2.2) 6.7 (2.4) 7.0 (2.4) 7.0 (4.8)
Walking ability 6.3 (2.8) 6.2 (2.3) 5.5 (2.0) 7.0 (2.7)
Normal work 8.1 (2.2) 8.5 (2.1) 8.5 (1.7) 7.2 (2.9)
Relations 6.2 (2.5) 5.3 (3.3) 6.5 (1.9) 7.0 (4.8)
Sleep 7.1 (3.0) 5.8 (3.5) 8.8 (1.9) 7.4 (3.0)
Enjoyment 7.4 (3.0) 6.8 (3.9) 8.3 (1.7) 7.4 (3.0)
Interference 7.1 (3.9) 6.7 (4.7) 7.7 (1.8) 7.1 (2.4)
SF-MPQ-2
Continuous pain 5.2 (2.0) 5.6 (0.9) 4.5 (3.0) 5.3 (2.2)
Intermittent pain 4.4 (2.5) 4.7 (2.4) 4.2 (2.6) 4.3 (3.1)
Neuropathic pain 2.7 (1.9) 2.7 (2.2) 2.1 (1.8) 3.2 (1.7)
Affective descriptors 4.0 (2.6) 3.9 (2.8) 2.0 (1.5) 5.6 (2.4)
Total 4.1 (1.7) 4.2 (1.5) 3.3 (2.0) 4.5 (2.0)
Oswestry Low Back Pain Disability Questionnaire
Total 49.2 (17.6) 55.8 (19.4) 48.8 (19.9) 43.0 (15.0)
PSEQ
Total 21.3 (12.8) 16.5 (15.8) 27.0 (7.7) 22.6 (12.2)
SF-12
PCS 33.5 (5.8) 34.5 (5.8) 32.7 (6.0) 33.1 (6.7)
MCS 35.7 (11.2) 34.7 (14.7) 43.4 (10.0) 30.4 (4.6)
HADS
Anxiety 10.1 (4.0) 10.3 (5.2) 7.5 (3.4) 12.0 (1.2)
Depression 9.7 (4.1) 11.0 (4.8) 6.8 (3.9) 10.4 (3.4)
Pain Catastrophizing Scale
Rumination 12.5 (3.9) 11.7 (4.9) 11.5 (4.0) 14.2 (2.5)
Magnification 7.1 (3.3) 6.8 (3.3) 6.3 (4.3) 8.0 (3.2)
Helplessness 15.7 (4.4) 16.3 (4.8) 11.7 (4.4) 18.0 (4.8)
Total 35.2 (11.1) 34.8 (11.7) 29.5 (12.3) 40.2 (9.0)
EQ-5D-5L index 0.41 (0.30) 0.43 (0.29) 0.40 (0.21) 0.39 (0.35)
Expectation of benefit 3.3 (1.7) 2.7 (2.4) 3.5 (0.6) 3.8 (1.1)
MCS, mental component summary; PCS, physical component summary.
a For some outcomes only 14 participants contributed data.
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TABLE 9 Summary of primary and secondary outcomes at all follow-up points
Outcome
Follow-up time point, mean score (SD)
6 weeks 3 months 6 months
Sham
group
(n= 2)
Intervention
group (n= 5)
Sham
group
(n= 3)
Intervention
group (n= 4)
Sham
group
(n= 3)
Intervention
group (n= 5)
BPI (0–10)
Worst pain 5.0 (2.8) 7.8 (1.9) 7.3 (3.0) 7.8 (1.7) 6.3 (4.7) 6.0 (3.5)
Least pain 4.0 (1.4) 5.2 (2.5) 7.0 (3.6) 5.3 (2.2) 5.3 (4.5) 5.0 (2.8)
Average pain 4.5 (2.1) 6.2 (2.5) 6.0 (2.6) 6.3 (2.5) 5.3 (4.5) 5.6 (2.6)
Pain now 5.0 (2.8) 6.6 (2.1) 6.3 (3.0) 5.8 (2.1) 6.0 (4.6) 5.2 (3.7)
Pain severity 4.6 (2.3) 6.5 (2.1) 6.7 (3.0) 6.3 (2.1) 5.8 (4.5) 5.5 (3.1)
General activity 5.0 (4.2) 6.2 (2.4) 6.7 (2.3) 7.3 (1.9) 6.0 (5.3) 5.6 (3.6)
Mood 4.5 (2.1) 7.2 (1.9) 7.0 (3.6) 7.8 (2.1) 5.3 (5.0) 5.6 (3.6)
Walking ability 4.0 (1.4) 7.2 (2.6) 5.3 (1.5) 6.0 (2.9) 4.3 (4.9) 5.0 (4.6)
Normal work 5.5 (0.7) 7.2 (2.6) 6.0 (2.0) 6.8 (2.8) 5.0 (5.0) 6.0 (4.7)
Relations 3.5 (2.1) 6.2 (3.4) 5.7 (4.0) 7.5 (1.9) 4.0 (5.3) 5.2 (3.2)
Sleep 6.5 (4.9) 8.0 (1.9) 7.0 (2.6) 6.3 (2.9) 4.3 (5.1) 6.0 (4.7)
Enjoyment 4.5 (2.1) 7.6 (2.3) 7.7 (2.5) 7.0 (2.2) 4.7 (4.7) 6.2 (3.3)
Interference 4.8 (2.1) 7.1 (1.9) 6.5 (2.4) 6.9 (2.2) 4.8 (4.9) 5.7 (3.8)
SF-MPQ-2
Continuous pain 3.8 (3.2) 4.9 (3.1) 6.3 (3.4) 3.9 (1.4) 4.1 (3.7) 3.3 (2.6)
Intermittent pain 4.4 (3.7) 3.7 (2.5) 4.9 (3.0) 3.7 (3.5) 3.5 (2.9) 3.6 (3.8)
Neuropathic pain 1.7 (1.8) 4.0 (3.2) 2.5 (1.5) 2.0 (0.9) 3.6 (3.4) 3.0 (2.9)
Affective descriptors 4.4 (4.8) 4.6 (3.0) 5.6 (4.0) 5.4 (1.2) 2.5 (2.5) 3.7 (2.8)
Total 3.5 (3.3) 4.2 (2.3) 4.8 (2.6) 3.6 (1.5) 3.5 (2.9) 3.4 (2.8)
Oswestry Low Back Pain Disability Questionnaire
Total 36.0 (17.0) 48.4 (20.2) 56.0 (14.4) 39.0 (9. 9) 42.6 (34.0) 39.9 (26.0)
PSEQ
Total 33.5 (10.6) 21.2 (15.3) 27.7 (9.6) 31.8 (14.1) 28.3 (21.7) 33.2 (19.4)
SF-12
PCS 38.8 (10.3) 33.7 (8.6) 38.5 (6.8) 40.8 (11.0) 34.4 (12.5) 39.5 (13.7)
MCS 43.6 (15.4) 31.3 (7.9) 35.7 (7.8) 37.8 (2.6) 47.2 (22.1) 38.1 (13.5)
HADS
Anxiety 7.0 (1.4) 12.8 (4.4) 8.3 (3.8) 11.5 (4.6) 6.7 (5.7) 10.0 (3.9)
Depression 4.0 (4.3) 10.8 (6.7) 8.0 (3.5) 9.5 (5.5) 7.7 (8.1) 8.4 (7.1)
Pain Catastrophizing Scale
Rumination 11.0 (1.4) 12.4 (4.9) 15.0 (1.0) 11.8 (4.8) 15.8 (3.8) 14.4 (5.5)
Magnification 8.0 (1.4) 6.6 (2.9) 10.3 (0.6) 5.0 (3.5) 19.5 (3.5) 13.8 (5.9)
Helplessness 14.0 (2.8) 15.0 (7.0) 13.7 (6.5) 15.0 (8.9) 16.7 (6.1) 15.5 (9.0)
Total 33.0 (5.6) 34.0 (14.0) 19.0 (6.6) 32.7 (17.2) 16.7 (7.6) 16.0 (7.4)
EQ-5D-5L index 0.67 (0.30) 0.43 (0.33) 0.42 (0.10) 0.62 (0.28) 0.60 (0.50) 0.51 (0.41)
Satisfaction 6.3 (3.8) 6.6 (0.9) 7.3 (1.2) 7.5 (0.6) 9.7 (0.6) 6.0 (2.1)
MCS, mental component summary; PCS, physical component summary.
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Blinding to treatment allocation
To test the fidelity of blinding, participants were asked to guess which allocation group they had been
randomised to, prior to being unblinded at the end of the study. Only one out of eight participants who
completed the study correctly guessed their allocation group. The blinded outcome assessor correctly
guessed the allocation group for four of the nine participants.
Health economics analysis
Given the importance of health economics evidence in informing decision-making, the incorporation of a
health economics work package as part of a feasibility study can inform the delivery of a robust trial in the
future, evaluating clinical effectiveness and cost-effectiveness. The main objective of the health economics
analysis was to assess the feasibility of collecting data and produce an appropriate framework for a future
full economic evaluation. This included a description of the main resource and cost drivers during the
patient pathway in delivering the intervention and an assessment of collecting resource use information
based on a resource use questionnaire devised for the feasibility study. An assessment of the performance
of two preference-based health-related quality of life measures – the SF-12 (SF-6D)55 and EQ-5D-5L54 –
within the feasibility study was also proposed in the original health economics analysis plan.
We intended to present both of the scores from the full EQ-5D (EuroQol-5 Dimensions) questionnaire,
that is, the EQ-5D-5L descriptive system and the EQ-5D VAS, to present a comprehensive picture of
patient-reported outcomes. Patients are asked to assess their health state on five dimensions – mobility,
self-care, usual activities, pain/discomfort and anxiety/depression – using five levels ranging from ‘no
problems’ to ‘severe problems’. A single summary index is obtained by applying a formula that attaches
weights to each of the levels in each dimension. This formula is based on the valuation of EQ-5D health
states from a general population sample in the UK.64 The EQ-5D VAS is a thermometer-type vertical 20-cm
scale with the end points of best imaginable health state (at the top) and worst imaginable health state
(at the bottom) having numerical values of 100 and 0 respectively. This is a self-rated valuation and
represents the respondents’ views of their health state and how it has affected their life on the day.
TABLE 10 Summary of adverse events
Participant
number
Description of adverse
event
Relationship to IMP,
as judged by the
Principal Investigator
Seriousness of the adverse
event, as judged by the
Principal Investigator
Randomisation
group
1 Flare-up of LBP after the
randomised procedure
Expected reaction,
related to the IMP
Not serious Sham
4 Flare-up of LBP 5 months
after the randomised
procedure
Expected reaction,
related to the IMP
Not serious Intervention
7 Urinary incontinence Unexpected reaction,
not related to the IMP
Serious adverse event
(required overnight stay in
hospital)
Intervention
Swelling at site of
injections
Expected reaction,
related to the procedure
but not to the IMP
Serious adverse reaction
(required overnight stay in
hospital)
Flare-up of LBP after the
randomised procedure
Expected reaction,
related to the IMP
Not serious
Flare-up of LBP 5 months
after the randomised
procedure
Expected reaction,
related to the IMP
Not serious
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The utilities derived from the EQ-5D-5L and SF-6D were converted into QALYs to present a profile of QALY
gains/losses over time.
As this was not a full trial, no inferential statistical comparisons of health-related quality of life or service
use between the intervention group and the control group were planned. Instead, the focus was on
reporting descriptive findings for the two groups at baseline and at the follow-up points to inform a
suitable framework for a future economic evaluation if the findings from the feasibility study could be used
to inform a future definitive study.
For the feasibility study, the perspective adopted was that of the UK NHS, focusing on primary and
secondary resource use. However, given the impact of back pain on the patient and wider society
(e.g. because of reduced/lost work productivity), a preliminary assessment of employment-related
outcomes using the SPS 660 was reported as part of the trial outcomes. The economic analysis was
conducted using IBM SPSS Statistics version 22 (IBM Corporation, Armonk, NY, USA).
Literature review
As part of the assessment of the feasibility of undertaking a future full economic analysis, a structured,
rapid review of the literature was undertaken (see Appendix 9). This rapid review identified two partial
economic evaluations (costs of FJIs)65,66 and one study that evaluated health-related quality of life.37 We
found limited economic evidence, with no cost-effectiveness studies identified of diagnostic or therapeutic
FJIs. In undertaking any future trial, the feasibility of considering longer-term horizons should be fully
assessed, for example whether a model-based analysis can be conducted to robustly extrapolate beyond
the trial horizon, based on the suitability and quality of external literature sources.
Identification of the main resource and cost drivers associated with the delivery of
facet-joint injections
A descriptive profile of resource use and costs was developed in consultation with the trial team to
understand the opportunity costs associated with the delivery of the intervention. These were valued
in Great British pounds in 2016 prices based on published unit costs or other literature sources.10,67–69
The resource use reported at each of the trial visits was assessed with regard to whether it represented
(1) research costs (which would be identified and excluded from any intervention costs), (2) costs attributed
to routine usual NHS care or (3) opportunity costs (e.g. associated with additional staff time in managing a
patient following FJIs) as a result of the intervention.
The intervention costs were considered in the following stages:
l identification and screening of patients suitable for treatment (entry into the trial)
l delivery of the intervention or sham procedure
l delivery of the CPP programme
l follow-up assessments.
The identification and screening of patients occurred during a routine consultant-led outpatient pain clinic
appointment. The associated unit cost per patient was recorded as £148.03 for both groups.67 Delivery of
the intervention or sham procedure occurred at a routine day surgery unit at a cost of £691 per patient.
The procedure was identified from the NHS national schedule of reference costs for 2015–1668 as an
Injection of Therapeutic Substance into Joint for Pain Management (currency code AB19Z).
Delivery of the CPP programme had a mean cost of £2500 per patient.70 However, as this programme was
delivered to both groups, we excluded the CPP programme costs from the final cost analysis.
There were three follow-up assessments. Two assessments/data collection sessions were research-based,
nurse-led appointments and were not included in the costs. The 6-month follow-up appointment was
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conducted by a consultant at an outpatient pain clinic as part of routine aftercare post procedure at a cost
of £148.03 per patient for both groups.69
Health resource use
An assessment of the feasibility of gathering appropriate resource use data from a patient sample was a
major component of this evaluation. The resource use measure was developed by the clinical team based
on standard clinical practice for the management of LBP and included questions on primary and secondary
care resource use (e.g. hospital admissions, outpatient visits, GP surgery visits and medication use).
Feasibility of collecting resource use data
The resource use questionnaire was completed by the trial research assistant during scheduled visits to a
nurse-led outpatient pain management clinic and took approximately 60 minutes per visit to complete.
Although these are ‘research’ costs, the cumulative impact of collecting data will add to the costing of the
time/resources for any future trial.
The focus was on collecting information on consultations with the NHS health-care professionals who
would most likely be involved in the management of LBP. All costs were valued in Great British pounds
using a price year of 2016. Table 23 (see Appendix 9) summarises this resource use. As the trial period was
< 12 months, no discounting was applied to costs or outcomes. An additional question allowed patients to
report any other resources used outside of the main categories; however, no other reported resource items
were recorded.
Data on hospital contacts collected via the resource use questionnaire was compared with the data
collected on adverse events and serious adverse events to ensure that there was no overlapping of data
collected and, therefore, no double-counting of resource use. Prior to the analysis, appropriate decision
rules were put in place for the costing of hospital admissions. If a patient was reported as having been
admitted to hospital during the past 4 weeks, as a result of a serious adverse event, this was classified as
an emergency hospital admission (non-elective inpatient stay). If (in an expected minority of patient cases)
a hospital admission was for a condition unrelated to LBP, the reason for the unrelated hospital admission
was recorded but the hospital admission was not included in the analysis.
The findings from the trial identified neither serious adverse events resulting in a hospital admission nor any
other hospital admissions during the trial period. When documented adverse events were examined (n = 3
participants accounting for six health-care contacts), no additional impact on resource use was identified
as one of the following: (1) already documented within the resource use questionnaire; (2) no further action
or impact on resource use was documented; or (3) the adverse event was unrelated to the intervention.
In two cases an adverse event was reported by the patient but no further information was available.
The resource use questionnaire collected information on current prescribed analgesics and any other
medications at baseline. At the three follow-up time points, information on current analgesics and other
medications was also collected along with any changes in medication during the follow-up period. The
specific dates that prescriptions were issued, including the dates that any changes in medication occurred,
were unknown because medications were prescribed by the patients’ GPs rather than by the trial team.
Medication reported in the ‘other’ medication category that was not related to the treatment of LBP was
excluded following examination of the data by the trial Chief Investigator. The costs of medication were
then compiled for each time point and summated to give a total medication cost per group.
Resource use and costs
Table 11 summarises the NHS resource use for participants from baseline to 6 months’ follow-up. Overall,
the total number of primary care visits was the same across the groups over the time period of the trial
(seven GP visits recorded with a total cost per group of £252).67 No emergency department admissions or
hospital inpatient admissions (either elective or emergency) were recorded in either group. One outpatient
appointment was recorded in the intervention group (received FJIs) at a cost of £148.68
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The main numerical differences between the two groups occurred for medication use, with a total cost of
£48.83 (mean cost £12.21 per participant; SD £11.31) in the sham group and £562.51 (mean cost
£112.50 per participant; SD £81.25) in the intervention group, a mean difference of £100 per participant.
Further details of the medication use over each time point are provided in Table 12.
Although there are limitations of the analysis associated with the highly skewed costs and small sample
size, this suggests that a potential downstream effect of FJI is a subsequent increase in medication use and
associated costs within primary care.
Table 13 provides an estimation of the total mean costs of the FJI intervention and the sham procedure.
This shows that the FJI intervention was assessed as costing £118 more per patient than the sham
procedure.
Outcomes
At baseline all nine patients completed the EQ-5D assessment. However, at the follow-up data collection
points only six participants (two in the sham group and four in the intervention group) returned complete
assessments across all three time points.
TABLE 11 NHS resource use and costs by NHS sector between baseline and 6 months’ follow-up
Consultations for LBP
Visits
Total costs (aggregate of all follow-up
time points) (£)
Sham group
(n= 4)
Intervention group
(n= 5)
Sham group
(n= 4)
Intervention group
(n= 5)
Total GP visits
Number of visits/cost 7 7 252.00 252.00
Mean (SD) 1.75 (1.71) 1.4 (2.19) 63.00 (61.48) 50.40 (78.87)
Min., max. 0, 4 0, 5 0, 44.00 0, 180.00
Total outpatient pain clinic appointments
Number of visits/cost 0 1 0 148.03
Mean (SD)
Min., max.
Total hospital emergency inpatient admissions
Number of visits/cost 0 0 0 0
Mean (SD)
Min., max.
Total emergency department admissions
Number of visits/cost 0 0 0 0
Mean (SD)
Min., max.
Total medication costs
Total cost 48.83 562.51
Mean (SD) 12.21 (11.31) 112.50 (81.25)
Min., max. 1.21, 29.63 29.63, 231.76
Max., maximum; min., minimum.
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The baseline mean EQ-5D-5L and SF-6D utilities and EQ-5D VAS scores are presented in Tables 14 and 15,
respectively, which compare the values for those patients who completed the assessments (complete cases)
with the values for those who withdrew after completing the baseline assessments. As a point of reference,
utilities from a UK population with LBP are presented.71
At baseline, there were numerical differences in baseline EQ-5D-5L utilities, with those lost to follow-up
having very slightly numerically higher utilities than those in the sham and intervention groups (0.43 vs.
0.40 vs. 0.39). The minimum and maximum values indicate that there is potentially a wide range of scores
and the potential for heterogeneity within the patient sample. Although appropriate caution must be
exercised in the interpretation of these baseline scores, further examination of baseline differences in
utilities should be examined in any future trial. Brazier et al.71 reported that, on average, the SF-6D
generates utility values that are higher than those generated using the EQ-5D-5L and this is also reflected
in this trial sample. The SF-6D results show that those in the intervention group have a marginally higher
utility score than those who withdrew after the baseline assessment and those who received the sham
procedure (0.53 vs. 0.52 vs. 0.51).
TABLE 12 Overall costs of prescribed analgesic medication after facet-joint treatment
Follow-up time period
Randomisation group
Sham (n= 4) (£) Intervention (n= 5) (£)
From baseline to 6 weeks’ follow-up (visit 4)
Total 32.05 35.75
Mean (SD) 8.01 (12.04) 7.15 (12.68)
Min., max. 0, 25.78 0, 29.27
From 6 weeks’ follow-up to 3 months’ follow-up (visit 5)
Total 4.25 129.63
Mean (SD) 1.06 (2.13) 25.93 (30.94)
Min., max. 0, 4.25 0, 77.95
From 3 months’ follow-up to 6 months’ follow-up (visit 6)
Total 12.53 397.13
Mean (SD) 3.12 (3.82) 79.43 (58.95)
Min., max. 0, 7.75 23.25, 156.12
Total medication costs after treatment
Total 48.83 562.51
Mean (SD) 12.21 (11.31) 112.50 (81.25)
Min., max. 1.21, 29.63 29.63, 231.76
Difference between groups
Total cost difference 513.68
Mean cost difference 100.29
Max., maximum; min., minimum.
TABLE 13 Mean costs associated with the facet-joint intervention and the sham procedure
Mean cost
Randomisation group, mean (SD)
Mean cost differenceSham (n= 4) Intervention (n= 5)
Total cost (£) 75 (73) 193 (219) The intervention is £118 more expensive
per patient than the sham procedure
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The EQ-5D VAS results showed a different picture, with VAS scores ranging from 45.60 in the intervention
group to 47.67 in the group who withdrew after completing the baseline assessment and 58.75 in the
sham group, again showing the potential for heterogeneity in the patient sample.
Stanford Presenteeism Scale 6 scores at baseline
Scores on the SPS 6 range from 6 to 30, with lower scores indicating lower presenteeism and higher
scores indicating higher presenteeism.60 Higher presenteeism scores are associated with decreased
productivity and work quality. At baseline the sham group and the group lost to follow-up reported slightly
higher scores of 15.8 and 15.2, respectively, with the intervention group having the lowest mean score of
14.4, as shown in Table 16.
Stanford Presenteeism Scale 6 scores at the follow-up assessments
After treatment, at the follow-up assessments, the sham group still had slightly higher presenteeism scores
than those who received the intervention (Table 17). Although the intervention group showed a reduction
in presenteeism score at the 6-week time point, both groups tended to report higher presenteeism scores
after treatment than at baseline.
Comparison of utilities across assessment points
Table 18 summarises the utilities across the groups at the three follow-up points to 6 months using the
EQ-5D-5L and SF-6D. It is important to acknowledge the impact of missing data, with two participants in
the sham group missing data at the 6-week assessment, one participant from each group missing data
at the 3-month assessment and one participant from the sham group missing data at the 6-month
TABLE 14 Mean EQ-5D-5L and SF-6D utility scores at baseline
Outcome
Randomisation group
Group lost
to follow-up
Utilities by disease
(lower back pain)aSham Intervention
EQ-5D-5L utility score
n 4 5 5 265
Mean (SD) 0.402 (0.209) 0.387 (0.355) 0.429 (0.362) 0.635 (0.266)
Min. 0.147 –0.068 –0.0004 –0.181
Max. 0.619 0.816 0.802 1.000
SF-6D utility score
n 4 4 5 263
Mean (SD) 0.509 (0.068) 0.532 (0.073) 0.523 (0.064) 0.658 (0.144)
Min. 0.450 0.450 0.410 0.370
Max. 0.590 0.620 0.570 1.000
Max., maximum; min., minimum.
a A comparison of the EQ-5D and SF-6D utilities of patients with LBP conducted by Brazier et al.71
TABLE 15 Mean EQ-5D VAS score at baseline
EQ-5D VAS scorea
Randomisation group
Group lost to follow-up (n= 6)Sham (n= 4) Intervention (n= 5)
Mean (SD) 58.75 (23.94) 45.60 (9.32) 47.67 (22.46)
Min. 25.0 38.0 20.0
Max. 80.0 60.0 80.0
Max., maximum; min., minimum.
a Ranging from 0 (worst health) to 100 (best possible health).
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assessment. Although the small sample size precluded any formal assessment of missing data, this
highlights the importance of ensuring that outcomes are as complete as possible over the follow-up period
and, when necessary, that there are appropriate decision rules to handle missing data (e.g. suitable
imputation methods) for formal economic analysis in any future trial.
For the EQ-5D-5L, the sham group showed an increase in utility from 0.40 at baseline to 0.68 at 6 weeks.
This declined at 3 months to 0.42 before increasing to 0.60 at 6 months, indicating small changes during
the treatment and follow-up period. In the intervention group, the baseline score of 0.39 increased
slightly to 0.43 at 6 weeks and 0.62 at 3 months and then declined to 0.52 at 6 months. Although no
quantitative assessment (given the limitations of the data) can produce a reliable numerical magnitude of
TABLE 16 Stanford Presenteeism Scale 6 scores at baseline
SPS 6 score
Randomisation group
Group lost to follow-up (n= 5)aSham (n= 4) Intervention (n= 5)
Mean (SD) 15.8 (3.8) 14.4 (5.5) 15.2 (3.1)
Min. 11.0 6.0 11.0
Max. 20.0 20.0 18.0
Max., maximum; min., minimum.
a One missing response.
TABLE 17 Stanford Presenteeism Scale 6 scores at follow-up
SPS 6 score
Follow-up time point
6 weeks (visit 4) 3 months (visit 5) 6 months (visit 6)
Sham group
(n= 2)
Intervention
group (n= 5)
Sham group
(n= 3)
Intervention
group (n= 4)
Sham group
(n= 3)
Intervention
group (n= 5)
Mean (SD) 19.5 (3.5) 13.8 (5.9) 16.7 (6.1) 15.5 (9.0) 16.7 (7.6) 16.0 (7.4)
Min. 17.0 7.0 10.0 7.0 8.0 6.0
Max. 22.0 22.0 22.0 26.0 22 24.0
Max., maximum; min., minimum.
TABLE 18 Mean utility scores at follow-up
Outcome
Follow-up time point
6 weeks (visit 4) 3 months (visit 5) 6 months (visit 6)
Sham group
(n= 2)
Intervention
group (n= 5)
Sham group
(n= 3)
Intervention
group (n= 4)
Sham group
(n= 3)
Intervention
group (n= 5)
EQ-5D-5L utility score
Mean (SD) 0.675 (0.118) 0.433 (0.335) 0.418 (0.098) 0.617 (0.279) 0.597 (0.499) 0.520 (0.413)
Min. 0.592 0.013 0.352 0.204 0.021 0.018
Max. 0.758 0.762 0.531 0.802 0.893 0.841
SF-6D utility score
Mean (SD) 0.708 (0.244) 0.452 (0.080) 0.557 (0.096) 0.561 (0.160) 0.622 (0.249) 0.615 (0.149)
Min. 0.540 0.380 0.470 0.410 0.370 0.450
Max. 0.880 0.570 0.660 0.730 0.860 0.820
Max., maximum; min., minimum.
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effect, the direction of travel suggests that, overall, there are likely to be small effects on health-related
quality of life. The SF-6D scores were, in the main, higher than the EQ-5D-5L scores. At 6 weeks’ follow-up
the sham group reported a considerably higher score than the intervention group (0.71 vs. 0.45). However,
at 3 months’ and 6 months’ follow-up both groups reported the same utility scores: 0.56 at 3 months
increasing to 0.62 by the end of the trial.
The mean EQ-5D VAS scores at follow-up are presented in Table 19. A similar pattern of missing data was
seen. Overall, there were numerical differences between each time point in both groups, with the sham
group showing a very slight improvement in VAS score from baseline to 6 weeks (58.75 vs. 60.00), a
reduction in VAS score between 6 weeks and 3 months (60.0 vs. 43.33) and an improvement in VAS score
from 3 months to 6 months (43.33 vs. 53.33). In contrast, the intervention group showed a decline from
baseline to 6 weeks (45.60 vs. 38.33), an improvement between 6 weeks and 3 months (38.33 vs. 53.33)
and a decline from 3 months to 6 months (53.33 vs. 45.00).
Changes in quality-adjusted life-years
Given the potential inclusion of a cost–utility analysis within a future economic analysis, the utilities derived
from the EQ-5D-5L and SF-6D were translated into QALYs using the methodology outlined in Appendix 9.
Table 20 summarises the QALYs at each time point by group. With respect to the EQ-5D-5L, from baseline
to 6 months the mean (SD) QALY gain was 0.31 (0.32) in the sham group and 0.28 (0.15) in the intervention
group. The SF-6D produced slightly higher QALY gains at 6 months, with the sham group reporting a mean
(SD) gain of 0.32 (0.076) and the intervention group reporting a mean (SD) gain of 0.30 (0.044).
In the health economics analysis plan, the original intention was to compare the psychometric properties of
the EQ-5D-5L with those of the SF-6D using a similar set of analyses as reported by Mulhern et al.,72 to
inform the potential choice of preference-based measure of health-related quality of life in any future trial.
However, given the limitations presented by the small sample size (and within this the further impact of
missing data), this analysis could not be undertaken given that it did not meet any of the accepted criteria
in terms of a sufficient sample size to conduct appropriate tests associated with assessing the reliability and
validity of patient-reported outcomes.73
Health economics summary
The health economics results are purely descriptive and with such a small sample size we are appropriately
cautious about drawing any conclusions. The incorporation of an early-stage assessment of the
requirements and parameters for an economic analysis in a future trial has allowed a provisional
assessment of these, with evidence from the feasibility study providing a useful basis for the development
of a suitable framework. Because of the constraints presented, in-depth examination was not undertaken
and the provisional assessments (e.g. early assessment of the intervention costs associated with FJIs) must
be interpreted with caution. A key learning point was the need for health economics analysis to be
embedded into the feasibility study to ensure that important insights and lessons can be used to develop
TABLE 19 Mean EQ-5D VAS scores at follow-up
EQ-5D VAS score
Follow-up time point
6 weeks (visit 4) 3 months (visit 5) 6 months (visit 6)
Sham group
(n= 2)
Intervention
group (n= 3)
Sham group
(n= 3)
Intervention
group (n= 3)
Sham group
(n= 3)
Intervention
group (n= 5)
Mean (SD) 60.00 (28.28) 38.33 (10.41) 43.33 (25.17) 53.33 (25.17) 53.33 (47.26) 45.00 (29.15)
Min. 40 30 20 30 0 10
Max. 80 50 70 80 90 80
Max., maximum; min., minimum.
The mean EQ-5D VAS scores shown above are derived from the VAS health scale. When a VAS score was missing the BOX
health scale54 was used as a substitute. If the VAS and the BOX scale scores differed, the mean of both scores was used as
a substitute.
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the framework for an economic analysis within a future trial. There are still questions to address but, even
with the basic assessment carried out during this feasibility study, we have a good basis on which to take
this development forward.
It seems clear that the study population are ‘users’ of health services, although there was little impact of
the intervention on secondary care, with the main drivers of subsequent health resource use being
associated with medications within primary care. Although the current resource use measure appears to
capture relevant cost drivers, further work on developing a more precise measure (such as utilising routine
secondary care data) to capture all relevant costs should be undertaken. Another possible area for
consideration is the potential for imbalances between the groups at baseline. In a full randomised
controlled trial, adjustment for baseline outcomes and other factors may be required. Although the
feasibility study was designed to capture a UK NHS perspective only, the potential impact on patients,
families and the wider society should be carefully considered in any future trial to capture the full picture.
The EQ-5D-5L and SF-6D data reflect the impact on health-related quality of life that the study participants
experienced. Although formal conclusions cannot be drawn on the merits of either measure, the consensus
from the team in light of this provisional investigation is that the EQ-5D-5L is likely to be the preferred
measure, given its use in previous studies of back pain and its recommendation by UK decision-making
bodies such as NICE74,75 as the primary method of deriving QALYs. Further exploration of the findings from
the feasibility study compared with the findings of other studies using these measure should be undertaken
to fully rationalise the selection of appropriate outcomes to inform a future economic evaluation.
Study timelines
The start date of the study was delayed by 18 months (546 days), with 244 days taken to obtain NHS
permission to recruit after obtaining a favourable research ethics opinion (Figures 4 and 5). A no-cost
negotiated 1-month extension period was granted by the funder to allow for collection of follow-up data
and delivery of the final report 45 days after collection of the final outcome data.
TABLE 20 Mean QALY gain from baseline to 6 months
Outcome
Time point
Total QALY gain
6 weeks
(baseline to visit 4)
3 months
(visit 4 to visit 5)
6 months
(visit 5 to visit 6)
Sham
group
Intervention
group
Sham
group
Intervention
group
Sham
group
Intervention
group
Sham
group
Intervention
group
EQ-5D-5L-derived QALY gain
n 2 4 2 4 2 4 2 4
Mean (SD) 0.075
(0.003)
0.059
(0.038)
0.068
(0.014)
0.069
(0.032)
0.167
(0.015)
0.155
(0.085)
0.309
(0.320)
0.283
(0.152)
Min. 0.073 0.007 0.058 0.023 0.156 0.028 0.290 0.060
Max. 0.076 0.094 0.077 0.094 0.178 0.200 0.330 0.370
SF-6D-derived QALY gain
n 2 3a 2 3a 2 3a 2 3a
Mean (SD) 0.076
(0.017)
0.062
(0.007)
0.077
(0.023)
0.064
(0.014)
0.165
(0.036)
0.151
(0.037)
0.318
(0.076)
0.300
(0.044)
Min. 0.064 0.055 0.060 0.047 0.139 0.107 0.260 0.250
Max. 0.089 0.071 0.093 0.078 0.191 0.185 0.370 0.330
Max., maximum; min., minimum.
a One additional missing response because of missing data at baseline.
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Q1 Q3 Q1 Q3 Q1 Q3 Q1 Q3
Delay in study start date (546 days)
Time taken to obtain research and development approval (350 days)
New study duration (639 days)
Recruitment period (252 days)
Follow-up period (432 days)
Final report due
1 January 
2014
Original
contract
start date
1 October
2014
Provisional
start date
1 July 2015
New study
start date
22 January 
2016 First
participant
recruited
30 September 
2016 New end 
of recruitment
31 July 2016
Original
end of
recruitment
31 March 
2017
End of
study
15 May 2017
Deadline for
HTA report20 January 2016
NHS permission
(research and
development
approval)
7 May 2015
MHRA
approval
4 February 
2015
Provisional
sponsorship
given
19 December 
2015 Final
declaration of
sponsorship
21 May 2015
REC
favourable
opinion
2014 2015 2016 2017
15 May 2017
1 January 2014 to 1 July 2015
4 February 2015 to 20 January 2016
1 July 2015 to 31 March 2017
22 January to 30 September 2016
22 January 2016 to 29 March 2017
FIGURE 4 Study timelines and milestones. REC, Research Ethics Committee.
D
O
I:10.3310/hta21740
H
EA
LTH
TECH
N
O
LO
G
Y
A
SSESSM
EN
T
2017
VO
L.21
N
O
.74
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2017.
This
w
ork
w
as
produced
by
Snidvongs
et
al.
under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth.
This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,
the
fullreport)
m
ay
be
included
in
professionaljournals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.
A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:
N
IH
R
Journals
Library,
N
ationalInstitute
for
H
ealth
Research,
Evaluation,
Trials
and
Studies
C
oordinating
C
entre,
A
lpha
H
ouse,
U
niversity
of
Southam
pton
Science
Park,
Southam
pton
SO
16
7N
S,
U
K
.
35
Month
Preparation
Protocol refinement
Statutory and regulatory requirements
Prepare study documentation
Recruitment and training of staff
Promotion of project in clinics
Fieldwork
Ongoing identification and recruitment
of patients
Outcome questionnaires – baseline
Outcome questionnaires – 6 weeks
after intervention
Outcome questionnaires – 3 months
after intervention
Outcome questionnaires – 6 months
after intervention
Intervention
Diagnostic injections
Facet-joint injections or sham procedure
Combined physical and
psychological programme
Training of physiotherapists
Delivery of programme
Analysis and reporting
Data coding, entry and cleaning
Analysis
Report writing
Dissemination of results
Management
Trial management group meetings
Trial steering committee meetings
– 4 – 3 – 2 – 1
2015 2015 2016 2017
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
M
a r
c h
A
p
r i
l
M
a y
J u
n
e
J u
l y
A
u
g
u
s t
S e
p
t e
m
b
e r
O
c t
o
b
e r
N
o
v e
m
b
e r
D
e c
e m
b
e r
J a
n
u
a r
y
F e
b
r u
a r
y
M
a r
c h
A
p
r i
l
M
a y
J u
n
e
J u
l y
A
u
g
u
s t
S e
p
t e
m
b
e r
O
c t
o
b
e r
N
o
v e
m
b
e r
D
e c
e m
b
e r
J a
n
u
a r
y
F e
b
r u
a r
y
M
a r
c h
A
p
r i
l
M
a y
× × × × × ×
× ×
FIGURE 5 Study Gantt chart.
RESU
LTS
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
36
Chapter 4 Discussion
Summary of findings
The overarching aim of the FACET feasibility study was to assess the feasibility of conducting a definitive
study to evaluate the clinical effectiveness and cost-effectiveness of FJIs compared with a sham procedure
in patients with non-specific LBP of > 3 months’ duration.
We were unable to meet our feasibility objective of a recruitment target of 60 randomised LBP patients
across three investigative sites. Instead, we were able to randomise only nine patients in one investigative
site. However, we believe that we met our other pre-stated feasibility objectives within the constraints of
this being a single-centre study with a small sample size: (1) we were able to select patients into the study
using a joint clinical and diagnostic approach; (2) we have demonstrated successful standardisation of
the methods of FJI and the sham procedure, using the Delphi method to generate consensus among
interventional pain specialists in the UK; (3) we were able to carry out the sham procedure (periarticular
injections with saline) in participants randomised to the control group; (4) the sham control study design
was accepted by the clinicians involved in the study and was also deemed acceptable by patients; and
(5) we were able to retain patients over the 6 months of follow-up.
The small number of participants recruited to the study and the feasibility design preclude us from drawing
any conclusions on the clinical effectiveness or cost-effectiveness of intra-articular lumbar FJIs in the
management of non-specific LBP. Additionally, although eight out of the nine patients randomised
completed the study, the small sample size precludes any definitive conclusions being made about patient
retention. However, the clinical procedures appeared to be safe and well tolerated, with no significant
adverse events related to the steroid injection. Furthermore, we were able to successfully collect clinical
and economic outcomes from the majority of the patients over the duration of the study.
Numerical differences between the groups were identified in the feasibility study (particularly with regard
to increased medication costs in the intervention group) that warrant further attention, particularly given
the inherent skewness in the data and the very small sample size.
The remainder of this chapter considers in more detail the findings of the feasibility study in terms of the
detailed objectives, reviews the practical problems that were experienced and identifies the key learning
outcomes for any definitive future trial in this area.
To assess the eligibility criteria and recruitment and retention of patients in the two
treatment arms
Recruitment took place at only a single centre, largely because of the delay in study set-up and the
decision by the funder to terminate the study early because of the lack of time available to open the other
two sites. A number of reasons for this delay in set-up and time to first patient recruitment have been
identified, including regulatory issues, staffing problems, specific recruitment challenges, factors affecting
clinician and patient participation and the study population itself.
An unexpectedly high number of patients needed to be screened to identify eligible patients. The actual
participant screening-to-recruitment ratio was 70 : 1 (628 : 9), which contrasts with the expected prestudy
ratio of 17 : 1 (1000 : 60). The screening criteria and recruitment rates were discussed at each TMG
meeting and it was perceived by some members of the group that the inclusion and exclusion criteria may
have excluded potentially eligible patients, such as those aged > 70 years who would otherwise have
been suitable.
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Over the period of the trial, five participants (31%) dropped out of the study after giving consent but
before receiving the diagnostic test (see Figure 3). This compared with our expected level of attrition. We
were able to collect study data from participants at baseline and at the various follow-up points. The level
of outcome completion varied across outcomes, with 11 out of 16 participants who completed the
baseline questionnaire returning incomplete data sets, ranging from entire questionnaire visits being
omitted to one section of a single questionnaire being missing or spoiled (illegible). Missing and
incomplete outcome data are detailed further in Appendix 11. Manual double data entry, considered to be
the gold standard for data transfer,76 was used by two independent researchers and ensured the high
quality of data entry onto the electronic database.
An apparently high level of participant retention was seen in this trial, with an average attrition rate of 11%,
that is, only one patient out of nine randomised failed to complete the final set of questionnaires at 6 months.
This compares favourably with the expected attrition rate of 20% defined in the protocol. However, given the
small sample size this estimate of attrition was very imprecise, with a 95% CI of 0.2% to 48%.
To assess the feasibility and acceptability of the two treatment arms from the point of
view of patients and their pain teams
A Delphi exercise was undertaken with interventional pain physicians in the UK to agree on the methods
for FJI and the sham procedure (see Appendix 6). The two treatments arms (FJIs and the sham procedure)
can therefore be considered to be feasible and acceptable by pain clinicians. Furthermore, all six pain
consultants at Barts Health NHS Trust screened and recruited participants to the study. Strong support was
also given from the surgeons and research physiotherapists involved in screening patients from the spinal
orthopaedic clinics at the centres involved in this study.
Of the 34 patients who met the eligibility criteria but who declined to take part in the study, none cited
the study design as the reason for not wishing to take part.
To assess the feasibility of the proposed definitive study design
We believe that this study did allow us to demonstrate the feasibility of the study design to inform a
definitive study. We were able to develop an appropriate active injection technique (intra-articular lumbar
FJI) and sham procedure. No patients refused participation on the grounds of randomisation to an active or
a sham procedure. We were able to maintain blinding of patients as only one of the eight participants
who completed the study correctly guessed their allocation group. The outcome assessors correctly
guessed four out of nine allocation groups over the period of the trial.
A key uncertainty going into this study was the feasibility of delivering a usual care CPP programme to
both study arms. The 2009 NICE guidelines for the early management of persistent non-specific LBP
(CG88)7 prescribed around 100 hours of a CPP programme over a maximum of 8 weeks for those who
have already received at least one less-intensive treatment such as an exercise programme, manual therapy
or acupuncture and who have ‘high disability and/or significant psychological distress’.7 However, following
careful discussion by the TMG and a review of the current evidence we instead decided to base delivery of
our CPP programme in this trial on the BeST trial,44 which recommended six sessions of group-based
therapy (up to 10 participants) of 90 minutes each. The study’s lead physiotherapist (SP) trained all of the
study physiotherapists across the three sites to deliver the CPP programme and all received a certificate
of training.
Three CPP programmes were consistently delivered at Barts Health NHS Trust, albeit to small groups of
participants (one to three participants per group); the BeST trial found that a group size of six to 10
participants was clinically effective and cost-effective and popular in clinical practice in that it allows for
group discussion and problem-solving.44 Six out of nine (67%) participants successfully completed the CPP
programme, defined in the protocol as having attended at least four out of the six sessions. The other
three participants failed to meet this protocol definition of CPP programme attendance because of
extenuating circumstances (illness, undisclosed personal reasons and travel abroad).
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Since our original trial proposal, the NICE guidelines (CG88)7 on the management of LBP have been
updated. The current 2016 NG5910 draws on evidence from the BeST trial44 and no longer specifies the
length or duration of the CPP programme, instead stating:
Consider a combined physical and psychological programme, incorporating a cognitive behavioural
approach (preferably in a group context that takes into account a person’s specific needs and
capabilities), for people with persistent LBP or sciatica:
l when they have significant psychosocial obstacles to recovery (for example, avoiding normal
activities based on inappropriate beliefs about their condition) or
l when previous treatments have not been effective.
© NICE 2017. Reproduced with permission from NG59. Low Back Pain And Sciatica in Over 16s:
Assessment and Management. Available from www.nice.org.uk/guidance/ng59. All rights reserved.
Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England.
All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no
responsibility for the use of its content in this product/publication
Thus, we believe that CPP programme delivery in our trial was well aligned with the latest NICE guidance.
To estimate outcome standard deviations to inform the power calculation for a
definitive study
We have reported the SDs for all proposed clinical and economic outcomes at baseline and follow-up.
However, given the small final sample size realised we express caution in using these SDs to inform the
sample size calculation for a future definitive study. Following their simulation analysis, Teare et al.77
recommended that an external pilot study has at least 70 measured subjects (35 per group) when
estimating the SD for a continuous outcome. Similarly, the sample size in this study was also inadequate to
provide a sufficiently precise estimate of attrition. Probably the only parameter for a future definitive study
that this study was able to estimate with precision was the screening/recruitment rate.
To finalise the protocol design, statistical plan, number of centres required and study
duration of the definitive study
Given the failure to meet the study recruitment target and the small number of patients recruited from one
centre, the study team deemed it inappropriate to present a finalised protocol for a definitive study on the
basis of this feasibility study.
Issues encountered and how they were resolved
This feasibility study encountered system-level barriers but no significant delays in obtaining research ethics
or MHRA approval.
Regulatory issues
The projected recruitment period for this feasibility study occurred during a time of change within research
governance, which in turn led to significant delays in regulatory approvals being granted (see Figure 4).
Delays were experienced in obtaining HRA approval and system errors led to further delays in obtaining
NIHR portfolio adoption and NHS permission. The large numbers of collaborating centres involved led to
delays in contracts being signed. The study team also noted the length of time taken for any issues to be
addressed at a local level.
Staffing issues
The changes in the study timeline meant that key members of the co-applicant team were unable to
commit to the study: the Chief Investigator (Richard Langford) and lead physiotherapist (Paul Watson)
retired from clinical practice, the trial co-ordinator was replaced and others had conflicting interests and
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priorities. A high staff turnover rate within the local research governance team, including several changes
of trial pharmacist and a change of trial monitor, resulted in some duplication of work, in part because of
inadequate handovers. Substantial amendments to the protocol were made to reflect staff turnover and
also on the request of the new trial monitor, resulting in further recruitment delays.
Recruitment challenges
The low recruitment rate from the pain clinics alone led to protocol amendments to allow for screening
at and recruitment from physiotherapy-based musculoskeletal clinics and spinal orthopaedic clinics
(see Appendix 10). A recruitment drive was put into place within the last 2 months of the recruitment
phase, led by a newly appointed trial mentor, using strategies to increase the number of patients eligible
for screening within the limitations of the study protocol. A no-cost recruitment extension period was also
granted by the funder.
However, it can be seen in Appendix 12 that, although the number of patients screened increased as a result,
the number of participants recruited did not. A future multicentre trial may wish to consider the early addition
of a recruitment co-ordinator to the core study team, to closely monitor the recruitment rate at each site and
implement a priori contingency plans with the sites’ Principal Investigators should the recruitment rate fall
below the predicted rate. Based on our experience, we would advise the appointment of a study mentor
(who is an experienced triallist) to review the recruitment rate at each site and to implement strategies to
improve this. This may include the appointment of additional research assistants to screen for suitable patients
from a wider range of clinics (e.g. associated community pain clinics and spinal orthopaedic clinics) and from
GP referral letters. Protocol amendments were made to reflect these changes (see Appendix 10). McDonald
et al.78 demonstrated that recruitment strategies can change as a result of pilot or feasibility phases of a study.
We conclude, however, that the target population for the study was not always being referred to the
hospital pain and spinal orthopaedic clinics. We were unable to explore this further in the feasibility study but
would propose this as an area for future exploration in terms of the definitive trial design. The recruitment
estimates used for the feasibility study were based on the clinical experience of the investigators and a
retrospective audit of procedures carried out at each of the three centres. It was initially believed that five
patients would be recruited from the pain clinics at Barts Health NHS Trust each week, with three patients
recruited each from Basildon and Thurrock University Hospitals NHS Foundation Trust in Basildon and the
Walton Centre NHS Foundation Trust in Liverpool. A comparison of the actual with the expected flow of
participants through the study is illustrated in Appendix 13. Although the actual number of participants
recruited in the study was lower than expected, it is hoped that this work will guide future research in this
area by providing more realistic and up-to-date data and by highlighting the areas in the recruitment
pathway that pose the greatest challenges to recruitment.
Clinician and patient participation
In their systematic review, Prescott et al.79 identified a number of factors that may affect clinician
participation in a study. These include time constraints and a lack of staff and training. Clinicians may
also have competing priorities during the study recruitment period, for example from involvement in
other trials. This feasibility study recruited from a busy NHS trust in which clinicians have time pressures
from usual clinical practice in the pain clinics as well as ongoing management duties. All of the study
interventions and pain consultant clinic appointments were scheduled alongside routine NHS appointments.
At the time of writing, the pain clinics at St Bartholomew’s Hospital at Barts Health NHS Trust accept
referrals via the NHS e-Referral Service (formerly Choose and Book) from a wide catchment area across the
country in addition to its local area in East London. Travel and travel costs can therefore be substantial for
some patients, some of whom have limited mobility because of their pain condition and may even require
hospital transport. Travel costs and the time taken to attend for appointments may therefore be a factor
contributing towards non-participation. Study participants may also have other commitments that preclude
their attendance at study visits, such as full- or part-time employment or caring for young children.
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Five out of sixteen patients who consented to take part in the study dropped out before treatment for
reasons that remain speculative. Of the nine patients who took part, six completed at least four sessions of
the CPP programme. It may be possible to improve participant retention in a definitive trial by including
more detailed information on the CPP programme in the participant information sheet and by involving
the public in its preparation to make the information easier to understand.
Study population
The study population presenting to pain clinics at Barts Health NHS Trust was noted to have complex pain
needs, often with co-existing radicular pain or chronic widespread pain conditions, in addition to suffering
from psychological distress. Although approximately 1050 new patients are referred and seen annually in
the pain clinics at St Bartholomew’s Hospital, it was clear that many of these ‘new’ patients were not new
to the pain services, having had previous spinal injections or surgery, for example. None of the patients
screened in the spinal orthopaedic clinics were eligible to take part in the study for these reasons and
many of the referrals also had radicular pain, indicative of a lumbar disc pathology.
No patients were recruited from the Tower Hamlets Persistent Pain Services at Mile End Hospital. The
London Borough of Tower Hamlets has a diverse ethnic population and experiences widespread
deprivation and low average health deprivation scores, with a high rate of population mobility.80 Although
an inability to speak English was not an exclusion criterion for the study, translation and patient advocacy
services for non-NHS study-related visits were not funded for. Language barriers have been highlighted by
previous researchers as being a negative influence on recruitment, with altruism noted to be an important
factor in deciding to take part.81 We believe that this could be an area for further investigation in a future
trial, to make research more accessible to diverse local populations.
The highest participant screening-to-recruitment ratio was seen in the community pain clinic at Essex
Lodge GP surgery, which has strong, established links to primary care and is located at the same site as the
GP surgery. Patients were thought to be referred to this pain service by the local GPs earlier in their pain
trajectory than in other pain clinics in this study. This feasibility study has demonstrated the need for more
primary care involvement at all stages of the study, from protocol design and patient screening and
recruitment to dissemination of the results. A need for improved referral pathways between the pain
services and some primary care providers has been identified.
Strengths and limitations
Many of the key uncertainties involved in undertaking a definitive study were addressed in this feasibility
study.
Major strengths of the study were the Delphi exercise, which was undertaken to obtain a consensus on
the procedural techniques, and that the interventional procedures themselves were shown to be safe and
reproducible. Furthermore, the positive response in nine out of 11 participants (82%, 95% CI 48% to
98%) following the single diagnostic lumbar facet medial branch nerve block indicates some accuracy of
the assessment performed by the clinical team in determining pain of lumbar facet-joint origin based on
history and clinical examination alone. However, the results are imprecise because of the small sample size.
We have shown that the CPP programme is deliverable at a single recruiting centre and that it was possible
to train the study physiotherapists to deliver the programme at each of the three planned recruitment
centres. We were able to retain most of the recruited participants for the duration of the study.
Embedding a health economics assessment into the feasibility study allowed us to obtain important insights
that can be used to develop the framework for an economic analysis within a future trial. Although the
feasibility study was not primarily designed to act as a formal microcosting exercise, we have endeavoured
to capture all salient aspects of the patient pathway relevant to the intervention using a triangulation of
data sources, including trial documentation and structured questions to the clinical experts and discussion
DOI: 10.3310/hta21740 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 74
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Snidvongs et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
41
with the trial team, with validation of any assumptions made throughout the costing procedure. We have
also been transparent in the costing methods employed, as detailed in Appendix 9. A recognised limitation
of our analysis is that the resource use questionnaire was not sufficiently comprehensive to capture all
health-care resource use nor did we investigate the potential for other approaches (including capturing
routine data in a systematic manner). In future feasibility studies we suggest that a worthwhile endeavour
would be to undertake a more ‘bottom-up’ exercise of costing, subject to trial resources being available to
do so. We therefore recommend that, in a future trial, the current measure is tested and challenged against
existing measures [e.g. search of the DIRUM (Database of Instruments for Resource Use Measurement);82
see Table 29 in Appendix 9], including investigating ways that data can be collated [such as using routine
sources such as Hospital Episode Statistics (HES) and/or utilising patient diaries to collect data, e.g. related to
primary care contacts and medication use].
The main weakness of the study was the failure to achieve our expected recruitment targets and the
consequent early closure by the funder. There were substantial system-level barriers that the study team
were unable to control (such as delays in obtaining HRA approval and changes in key study personnel),
which led to long delays in obtaining research governance approvals, and permission to recruit was
granted at only a single site.
It became clear early in the recruitment phase that many patients presenting to the pain clinics with LBP of
> 3 months’ duration were not suitable for the study and that patients screened in the spinal orthopaedic
clinics also did not meet the eligibility criteria. Despite employing additional strategies in the final stages of
recruitment, we can conclude that the patient population presenting to these hospital-based specialist
clinics was generally not suitable because of the complexity of their pain problems and that we may have
had better success in recruiting from primary care-based services.
We would advise caution in extrapolating the results of this study as the study took place at a single centre
in a secondary care setting. Patients presenting to primary care may additionally have lower levels of
functional disability, despite high levels of pain intensity.
The feasibility study resulted in a number of suggestions for refinements to data collection, including
resource use. One of the key balances has to be the development of a measure (method) of capturing
resource use that is sufficiently comprehensive and accurate enough to capture important and relevant
changes while not overburdening the trial in capturing extensive and irrelevant drivers of costs. The derived
measure was driven primarily by clinical expertise; however, this must of course be balanced with the
needs of the health economist in terms of having data of sufficient quality to undertake a comprehensive
and transparent costing exercise. Appendix 14 presents recommendations from reflecting on the current
measure of resource capture.
Because of the trial limitations, we were able to present only a descriptive profile using the EQ-5D-5L and
SF-6D to determine utilities; thus, any interpretation of our findings should be appropriately tentative.
The choice of which measure to use should also be considered further, given the potential for different
numbers of QALYs to be generated by different measures and the subsequent impact on calculations of
cost-effectiveness.73
Implications for a future definitive study
Neither of the research teams funded by the HTA programme to investigate the feasibility of carrying out a
definitive study to assess the use of lumbar FJIs for persistent non-specific LBP met the target recruitment
rate. Professor Underwood’s team concluded that a definitive study is indeed feasible, but that recruitment
from the pain clinics alone was insufficient.83 Both teams experienced significant delays in study set-up.
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Any future definitive trial must consider patient and public involvement at all stages of the research cycle,
including in the design and running of the trial and representation on the TMG.
Low back pain and sciatica were selected by the Trauma Programme of Care Board as their Pathfinder
Project; these projects were established by NHS England in 2013 to set up clear ‘end-to-end’ generic
pathways from primary care into specialised services as required, enabling collaborative commissioning and
incorporation of the latest evidence into the pathways. The National Low Back and Radicular Pain Pathway
201784 was updated following the publication of NG5910 and includes all of NICE’s recommendations.
Improved co-ordination and communication with GP practices is necessary for any future collaborative
work and we envisage working alongside the Pathfinder Project (in which spinal injections are not
recommended) to recruit patients from primary care with high levels of functional disability who may
benefit from such an intervention and rehabilitation at an earlier stage. One finding from the feasibility
study was the long duration of pain awareness among the study participants, which warrants further
investigation as this may reflect the time taken for patients to be referred to specialist clinics.
Based on our findings, we propose three research recommendations. First, we would agree with the
Underwood team that a definitive study is potentially feasible, with adjustments made to the target
population and increased primary care involvement, to enable patients to be screened earlier in their pain
trajectory. Second, a definitive study will need to draw on lessons learned from both research teams (such
as the recruitment enhancement strategies) and could involve a future collaboration between the two
research groups, combining the successful elements of the feasibility studies. The updated NICE guidelines10
recommended radiofrequency denervation of the lumbar facet-joint medial branch nerves in patients with
LBP that have not responded to less invasive treatments, following a positive diagnostic block; this is in
contrast to a recent Cochrane review that has not recommended its use.85 There is, however, new evidence
from a large multicentre Dutch trial that radiofrequency denervation offers no clinical benefit compared with
a sham procedure.86 Third, as both intra-articular injections and radiofrequency denervation are widely used
in the UK, we contend that there remains a need for future definitive studies to assess the clinical
effectiveness and cost-effectiveness of both of these procedures in the management of persistent LBP.
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Chapter 5 Conclusions
A successful trial can be defined as one that achieves success in recruitment and is able to answer theresearch questions. Although we have successfully demonstrated our ability to develop a robust study
protocol and deliver the intended interventions, and addressed many of the feasibility objectives, the
failure to achieve the target recruitment rate remains a key finding of this study. However, there are
lessons to be learned here that can be used to inform and improve patient recruitment for a future
definitive study. To optimise recruitment for a definitive study we would contend that any future studies
in this area should involve stronger collaborations with primary care physicians and musculoskeletal
physiotherapy teams to identify and recruit potential participants earlier in their pain trajectory, with the
aim of making these procedures more accessible to these patients who would not otherwise have been
referred on for specialist services.
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Conferences
The study protocol was presented as a poster at the International Association for the Study of Pain’s 16th
World Congress on Pain in Yokohama, Japan, in September 2016. The preliminary results were presented
as a poster at the British Pain Society’s 50th Anniversary Annual Scientific Meeting in Birmingham, UK, in
May 2017. The full study was presented as a poster at the European Pain Federation’s 10th Congress in
Copenhagen, Denmark, in September 2017; the critical appraisal of systematic reviews was also presented
as a poster at the same congress. The study has been accepted as a poster presentation at the Society for
Back Pain Research in Northampton, UK, in November 2017.
Thesis in preparation
The FACET feasibility study will form the basis of Dr Snidvongs’s Doctor of Medicine thesis entitled
‘Lumbar facet-joint injections for the management of chronic low back pain’. This will be submitted to the
University of Exeter in 2017.
Data sharing statement
We shall make data available to the scientific community with as few restrictions as feasible while retaining
exclusive use until the publication of major outputs. Requests for the data should be made to the
corresponding author (Dr Saowarat Snidvongs).
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Appendix 1 Search strategies for the literature
search of systematic reviews and meta-analyses of
randomised controlled trials of intra-articular lumbar
facet-joint injections for chronic low back pain
MEDLINE
Date range searched: 1966 to 6 February 2017.
# Search term Results
1 exp *LOW BACK PAIN/ 13,733
2 (“low back pain”).ti,ab 21,120
3 exp *ZYGAPOPHYSEAL JOINT/ 961
4 (“facet joint”).ti,ab 2227
5 exp *CHRONIC PAIN/ OR exp *PAIN/ 218,391
6 (lumbar OR paravertebral).ti,ab 91,494
7 exp *LUMBAR VERTEBRAE/ 26,956
8 1 OR 2 24,954
9 3 OR 4 2683
10 6 OR 7 98,948
11 5 AND 10 9560
12 8 OR 9 OR 10 OR 11 117,090
13 exp *INJECTIONS, INTRA-ARTICULAR/ 809
14 (“intra articular*”).ti,ab 12,196
15 (facet ADJ2 injection).ti,ab 143
16 (facet ADJ2 joint).ti,ab 2299
17 exp *FLUOROSCOPY/ 5060
18 (fluoroscop*).ti,ab 21,046
19 exp *THERAPEUTICS/ 2,895,415
20 (therap*).ti,ab 2,169,176
21 (“percutaneous spinal”).ti,ab 94
22 13 OR 14 12,630
23 15 AND 16 120
24 17 OR 18 23,098
25 19 OR 20 4,590,592
26 exp *INJECTIONS/ 20,026
27 (injection*).ti,ab 496,795
28 26 OR 27 505,646
29 21 AND 28 7
30 22 OR 23 OR 24 OR 25 OR 29 4,610,334
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# Search term Results
31 12 AND 30 49,755
32 (“systematic review*”).ti,ab 94,141
33 31 AND 32 1138
34 (“meta analysis”).ti,ab 88,442
35 31 AND 34 521
36 (“control* trial*” OR RCT).ti,ab 13,597
37 31 AND 36 179
38 33 OR 35 OR 37 1504
39 (facet).ti,ab 10,869
40 32 AND 39 123
EMBASE
Date range searched: 1966 to 6 February 2017.
# Search term Results
1 exp *LOW BACK PAIN/ 23,697
2 (“low back pain”).ti,ab 28,245
3 exp *ZYGAPOPHYSEAL JOINT/ 509
4 (“facet joint”).ti,ab 2999
5 exp *CHRONIC PAIN/ OR exp *PAIN/ 386,200
6 (lumbar OR paravertebral).ti,ab 123,427
7 exp *LUMBAR VERTEBRAE/ 7855
8 1 OR 2 35,444
9 3 OR 4 3251
10 6 OR 7 125,759
11 5 AND 10 16,010
12 8 OR 9 OR 10 OR 11 151,862
13 exp *INJECTIONS, INTRA-ARTICULAR/ 1884
14 (“intra articular*”).ti,ab 15,071
15 (facet ADJ2 injection).ti,ab 193
16 (facet ADJ2 joint).ti,ab 3056
17 exp *FLUOROSCOPY/ 6811
18 (fluoroscop*).ti,ab 34,353
19 exp *THERAPEUTICS/ 3,002,010
20 (therap*).ti,ab 3,111,511
21 (“percutaneous spinal”).ti,ab 138
22 13 OR 14 16,232
23 15 AND 16 165
24 17 OR 18 35,845
25 19 OR 20 5,235,530
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# Search term Results
26 exp *INJECTIONS/ 33,580
27 (injection*).ti,ab 635,413
28 26 OR 27 639,110
29 21 AND 28 11
30 22 OR 23 OR 24 OR 25 OR 29 5,270,243
31 12 AND 30 38,627
32 (“systematic review*”).ti,ab 118,882
33 31 AND 32 867
34 (“meta analysis”).ti,ab 117,968
35 31 AND 34 428
36 (“control* trial*” OR RCT).ti,ab 231,428
37 31 AND 36 2362
38 33 OR 35 OR 37 2906
39 (facet).ti,ab 12,624
40 32 AND 39 149
Cochrane Central Register of Controlled Trials
Date range searched: 1966 to 6 February 2017.
Search strategy
#1 MeSH descriptor: [Back Pain] explode all trees
#2 back near pain
#3 dorsalgia
#4 back disorder*
#5 backache
#6 MeSH descriptor: [Low Back Pain] explode all trees
#7 (lumbar next pain)
#8 (#1 or #2 or #3 or #4 or #5 or #6 or #7)
#9 MeSH descriptor: [Zygapophyseal Joint] explode all trees
#10 facet near joints
#11 zygapophysial*
#12 (#9 or #10 or #11)
#13 (#8 and #12)
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Appendix 2 Systematic review articles on
therapeutic lumbar facet-joint injections identified
from the database searches
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Source
First author, year of publication
Slipman
et al.,
200314
Boswell
et al.,
200587
Boswell
et al.,
200715
Staal
et al.,
200816
Staal
et al.,
200988
Datta
et al.,
200917
Chou
et al.,
200918
Henschke
et al.,
201019
Falco
et al.,
201220
Manchikanti
et al., 201521
Boswell
et al.,
201589
Manchikanti
et al., 201522
Vekaria
et al.,
201623
Manchikanti
et al., 201624
MEDLINE
EMBASE
CENTRAL
Other
sources
Reasons for
exclusion if
applicable
Published
update
Duplicate
publication
Intervention
not of
interest
A
PPEN
D
IX
2
N
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R
Journals
Library
w
w
w
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Appendix 3 Assessment of Multiple Systematic
Reviews (AMSTAR) checklist scores for the included
systematic reviews
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First author, year Item 1 Item 2 Item 3 Item 4 Item 5 Item 6 Item 7 Item 8 Item 9 Item 10 Item 11 AMSTAR scorea
Slipman, 200314 CA CA N N Y Y Y Y CA N CA 4
Boswell, 200715 CA CA Y CA Y Y Y Y CA N CA 5
Staal, 200816 Y Y Y N Y Y Y Y Y N CA 8
Datta, 200917 CA CA Y CA Y NA NA NA NA N CA 2
Chou, 200918 CA Y Y Y Y N Y Y N N CA 6
Henschke, 201019 CA CA N N Y Y Y Y Y Y N 6
Falco, 201220 CA Y Y CA Y Y Y Y Y N CA 7
Manchikanti, 201521 CA Y Y CA Y Y Y Y Y N N 7
Manchikanti, 201522 CA Y Y CA N Y Y Y Y N CA 6
Vekaria, 201623 Y Y Y Y Y Y Y Y Y Y CA 10
Manchikanti, 201624 CA Y Y CA N Y Y Y N N CA 5
CA, can’t answer; N, no; NA, not applicable; Y, yes.
a Maximum score 11.
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Appendix 4 Venn diagram to illustrate the
randomised controlled trials included in each
systematic review
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Systematic review paper
Slipman et al., 200313
Boswell et al., 200714
Falco et al., 201219
Staal et al., 200815
Datta et al., 200916
Chou et al., 200917
Henschke et al., 201018
Manchikanti et al., 201521
Manchikanti et al., 201623
Manchikanti et al., 201520
Vekaria et al., 201622
Fuchs
et al.,
200532
Revel
et al.,
199829
Carette
et al.,
199127
Marks
et al.,
199228
Lilius
et al.,
198926
Mayer
et al.,
200431 Manchikanti
et al., 200130
Manchikanti
et al., 200833
Kawu et al.,
201134
Celik et al.,
201135
Nash 198990
Yun et al.,
201236
Lakemeier et al.,
201338
Ribeiro
et al.,
201337
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Appendix 5 Participant information sheet
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Appendix 6 Delphi exercise
A web-based survey of pain specialists in the UK utilised the Delphi method to determine the choice ofneedle, injectate and volume of injection, as well as the choice of steroid, dose and volume and the
maximum dose of steroid. Of approximately 250 pain specialists consulted, 42 took part in the survey.
TABLE 21 Results of the Delphi exercise
Question Response (%)
Response
count
1. At what maximum steroid dose, do you think, reviewers and general sceptics could claim that a positive result for a
facet-joint injection was due to systematic action, rather than local benefit?
60 mg of methylprednisolone 25.0 10
80mg of methylprednisolone 22.5 9
100mg of methylprednisolone 20.0 8
120mg of methylprednisolone 32.5 13
Response (%)
Response
count
2. Which volume is closest to your choice in each facet-joint?
< 1ml 28.6 12
1ml 38.1 16
1.5 ml 21.4 9
Response (%)
Response
count
3. Assuming that we keep to a maximum of four joints, what steroid dose should we use in each joint?
10 mg of methylprednisolone per joint 40.5 17
20mg of methylprednisolone per joint 57.1 24
30mg of methylprednisolone per joint 2.4 1
Most likely,
% (n)
Likely,
% (n)
Not likely,
% (n)
Does not affect the
outcome, % (n) Rating average
Response
count
4. If we were not to use methylprednisolone, which of these two steroids would you prefer?
Triamcinolone 85.7 (36) 9.5 (4) 2.4 (1) 2.4 (1) 1.21 42
Dexamethasone 12.5 (4) 34.4 (11) 50.0 (16) 3.1 (1) 2.44 32
Response (%)
Response
count
5. The sham group should have a fluoroscopic guided needle placed
Next to the periarticular surface with no injection 38.1 16
Next to the periarticular surface with saline injected (same volume as the active group) 28.6 12
Intra-articular placement with only contrast injected 21.4 9
Intra-articular placement with contrast and placebo (saline) injection (same volume as the
active group)
11.9 5
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Appendix 7 Sample case report form
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
 
CASE REPORT FORM 
A multicentre double-blind randomised controlled trial to assess the clinical- 
and cost-effectiveness of facet-joint injections in selected patients with non-
specific low back pain: a feasibility study. 
Short title:     Facet-joint feasibility study 
Sponsor: Barts Health NHS Trust  
Representative of the Sponsor: 
 Dr Sally Burtles 
 Director of Research Services 
JRMO 
QM Innovation Building 
 5 Walden Street 
 London 
 E1 2EF 
 Phone: 020 7882 7265 
 Email: sponsorsrep@bartshealth.nhs.uk 
Chief investigator:   Dr Vivek Mehta 
Site principal investigator: 
Co-investigators:
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Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
Patient eligibility – inclusion criteria 
 
 
 
Inclusion criteria 
 Yes No 
1. Patient aged 18 to 70 years attending pain clinics identified during routine clinical 
assessment of non-specific low back pain 
  
2. Low back pain of greater than three months’ duration   
3. Average pain intensity score of 4/10 or more in the seven days preceding recruitment 
despite NICE recommended treatment 
  
4. Dominantly paraspinal (not midline) tenderness at two bilateral lumbar levels   
5. At least two components of NICE-recommended best non-invasive care completed, 
including education and one of a physical exercise programme, acupuncture, and 
manual therapy 
  
6. Patient is suitable for the facet- joint feasibility study   
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Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
Patient eligibility – exclusion criteria 
 
 
 
Exclusion criteria 
 Yes No 
1. Patient refusal to consent   
2. More than four painful lumbar facet-joints   
3. Patient has not completed at least two components of NICE-recommended best non-
invasive care, including education and one of a physical exercise programme, 
acupuncture, and manual therapy 
  
‘Red flag’ signs including thoracic pain, fever, unexplained weight loss, bladder or bowel 
dysfunction, progressive neurological deficit, and saddle anaesthesia 
  
5. Hypersensitivity to study medications   
6. Dominantly midline tenderness over the lumbar spine, any other dominant pain or 
radicular pain. 
  
7. Any major systemic disease or mental health illness that may affect the patient’s pain, 
disability and/or their ability to exercise and rehabilitate, as judged by the Principal 
Investigators 
  
8. Any active neoplastic disease, including primary or secondary neoplasm   
9. Pregnant or breastfeeding   
10. Previous lumbar facet-joint injections, spinal surgery or any major trauma or infection 
to lumbar spine. 
  
11. Patient with morbid obesity (body mass index of 35 or greater)   
12. Participation in another clinical trial of a investigational medicinal product or disease 
related intervention in the past thirty days 
  
13. Patient unable to commit to the six-month study duration   
14. Patient involved in legal actions or employment or benefit tribunals related to their low 
back pain 
  
15. Patient with a history of substance abuse   
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Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
Consent 
 
 
Date of patient consent 
 
_________________ 
Version of consent form used 
 
_________________ 
Baseline pain score (NRS)  up 7 
days preceding recruitment 
                 date taken: 
 
I confirm that this patient is eligible to enter the study  
–––––––––––––––––––––––––––––––––––––– 
 (signature of medical doctor on delegation log) 
Patient visit schedule 
 
 
 Date of visit(s) 
 
Visit 1 
 
Screening and informed consent 
Outcome questionnaires at baseline 
 
 
Visit 2 
 
Diagnostic test (medial branch nerve blocks) 
 
 
Visit 3 
 
Study procedure (facet-joint injections or sham 
procedure) 
 
 
 Combined physical and psychological programme 
 
Date of first session: 
 
Date of last session: 
 
Number of sessions attended: 
 
Visit 4 
 
Outcome questionnaires at 6 weeks 
 
 
Visit 5 
 
Outcome questionnaires at 3 months 
 
 
Visit 6 
 
Outcome questionnaires at 6 months 
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Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
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Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
Patient history 
To be completed by research assistant 
 
 
General health 
 
How long has the patient been aware of his/her non-specific low back pain? 
 
_______ 
 
_______ 
 Years Months 
   
 
In general, would the patient describe his/her health as: (tick box) 
  
 
Excellent  
 
Very good  
 
Good  
 
Fair  
 
Poor  
   
Occupation information 
 
What is the patient’s current work status? (tick box) 
 
 
 
 
Full time  
 
Part time  
 
Volunteer  
 Modified 
duties 
 
 
Disabled  
 Not 
working 
 
 
Homemaker  
 
Retired  
 Not 
applicable 
 
   
Type of work or occupation: 
_____________________________________________________________ 
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Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
Patient history 
To be completed by research assistant 
 
Did the patient’s illness cause him/her to stop working? Yes 
 
 No 
 
 Not 
applicable 
 
  
 Other (give reason): 
  
_______________________________________________________________ 
  
If the patient continued working, how many work days in the past 3 
months, prior to the procedure, did he/she miss due to pain? 
 
_______ days 
   
What was the patient’s level of activity prior to the procedure?   
 Hard 
manual 
work 
 
 
Lifting  
 
Walking  
 
Sedentary  
   
Social history 
 
Smoking 
Current 
smoker 
 
 
_______ 
cigarettes/day 
 
 
 
Ex-smoker 
 
 
 date stopped 
 
 Never 
smoked 
 
   
 
Alcohol 
 
_______ 
 
 Units consumed per week 
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Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
 
Patient history 
To be completed by research assistant 
 
 
Exercise per week: (tick box) >5 days 
 
 3-5 day 
 
 1-2 days 
 
 Less than 1 
day 
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Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
 
 
 
Visit 1 
 
Baseline 
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Visit 1- Baseline 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
Patient questionnaire 
To be completed by research assistant 
 
Treatments/hospitalisations/medications 
 
Has the patient seen a healthcare professional within the 
past 4 weeks due to pain? 
 
 
 
 _______ 
Emergency 
department visits 
_______ 
Length of stay in hospital 
  
_______ GP appointments 
  
_______ pain clinic 
 
 
 Other (give details): 
  
_______________________________________________________________ 
 
Current analgesics (name of medication, dosage and frequency) 
 
 
 
 
 
 
 
 
Other medications (name of medication, dosage and frequency) 
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Visit 1- Baseline 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
Patient’s expectation of benefit 
 
How much improvement in pain does the patient expect from the procedure?  (circle one) 
 
 
1 2 3 4 5 6 
 
 
Outcome questionnaires 
 
Has the questionnaire pack (set 1) been completed? Yes 
 
 No 
 
 
 
 
 
 
 
 
Expect no improvement Expect total improvement 
DOI: 10.3310/hta21740 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 74
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Snidvongs et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
87
Visit 1- Baseline 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
 
 
 
Visit 2 
 
Diagnostic test 
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Visit 1- Baseline 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
Diagnostic test (medial branch nerve blocks) 
To be completed by PI 
 
 
 
Study centre 
 
____________________________ 
 
 
Date of procedure 
 
____________________________ 
 
 
Time of procedure 
 
____________________________ 
 
 
Operator 
 
____________________________ 
 
 
Procedure details 
 
Number of injections 
 
____________________________ 
 
IMP injected 
 
1% lidocaine 0.5% per site 
 
  
Levels injected  
 
 
 
 
 
  
 
Post injection evaluation 1 (20 to 40 minutes after injection) 
To be completed by PI 
 
 
 
Time of evaluation 
 
____________________________ 
 
 
Minutes after injection 
 
____________________________ 
 
 
Please rate the patient’s current level of pain on a numerical rating scale (NRS) of 0-10. (0 is no pain and 10 is worst 
pain): 
 
Patient’s current pain score = 
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Visit 1- Baseline 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
 
Post injection evaluation 2 (180 to 240 minutes after injection) 
To be completed by PI 
 
 
 
Time of evaluation 
 
____________________________ 
 
 
Minutes after injection 
 
____________________________ 
 
 
Please rate the patient’s current level of pain on a numerical rating scale (NRS) of 0-10. (0 is no pain and 10 is worst 
pain): 
 
Patient’s current pain score =  
 
 
 
 
 
Investigator decision: positive test is a 50% or greater pain relief lasting more than 30 minutes (circle one) 
 
Positive (for randomisation)               Date of randomisation ________________ 
 
Negative (end of study) 
 
 
Visit 3- Study procedures form the ‘blinded CRF' 
This section is to be completed by the PI and kept separately in a locked filing cabinet until unblinding 
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Patient identification number __________ 
 
Patient initials __________ 
Investigator’s initials __________ 
 
Date __________ 
 
CASE REPORT FORM 
A multicentre double-blind randomised controlled trial to assess the clinical- 
and cost-effectiveness of facet-joint injections in selected patients with non-
specific low back pain: a feasibility study. 
Short title:     Facet-joint feasibility study 
Sponsor: Barts Health NHS Trust 
Representative of the Sponsor: 
 Dr Sally Burtles 
 Director of Research Services 
JRMO 
QM Innovation Building 
 5 Walden Street 
 London 
 E1 2EF 
 Phone: 020 7882 7265 
 Email: sponsorsrep@bartshealth.nhs.uk 
Chief investigator: Dr Vivek Mehta 
Site principal investigator: 
 
This section is the ‘blinded CRF' to be completed by the PI and kept separately in a locked filing cabinet 
until unblinding 
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Patient identification number __________ 
 
Patient initials __________ 
Investigator’s initials __________ 
 
Date __________ 
 
 
Visit 3 
 
Study procedure 
 
Study procedure (facet-joint injections or sham procedure) 
To be completed by PI 
 
 
 
Study centre 
 
____________________________ 
 
 
Date of procedure 
 
____________________________ 
 
 
Time of procedure 
 
____________________________ 
 
 
Operator 
 
____________________________ 
 
 
Procedure details 
 
Number of injections 
 
____________________________ 
  
Levels injected  
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CPP 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
 
 
 
 
Combined physical and 
psychological 
programme 
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CPP 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
Combined physical and psychological programme 
 
 
 
Study centre 
 
____________________________ 
 
 
  
Date attended 
 
Outcomes delivered 
 
Session 1 
 
____________________________ 
Y/N 
 
Session 2 
 
____________________________ 
Y/N 
 
Session 3 
 
____________________________ 
 
 
Session 4 
 
____________________________ 
 
 
Session 5 
 
____________________________ 
 
 
Session 6 
 
____________________________ 
 
 
If all outcomes not delivered please provide further details: 
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Visit 4 – Outcome measures at 6 weeks 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
 
 
 
Outcomes 
  
6 Weeks Post 
Intervention 
DOI: 10.3310/hta21740 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 74
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Snidvongs et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
95
Visit 4 – Outcome measures at 6 weeks 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
Patient questionnaire 
To be completed by research assistant 
 
 
Treatments/hospitalisations/medications 
 
Has the patient seen a healthcare professional within the 
past 4 weeks due to pain? 
 
 
 
 _______ 
Emergency 
department visits 
_______ 
Length of stay in hospital 
  
_______ GP appointments 
  
_______ pain clinic 
 
 
 Other (give details): 
  
_______________________________________________________________ 
 
Current analgesics (name of medication, dosage and frequency) 
 
 
 
 
 
 
 
 
Other medications (name of medication, dosage and frequency) 
 
 
 
 
 
 
 
Patient’s expectation of benefit 
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Visit 4 – Outcome measures at 6 weeks 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
 
How satisfied is the patient with the treatment received?  (circle one) 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
Outcome questionnaires 
 
Has the questionnaire pack (set 2) been completed? Yes 
 
 No 
 
 
 
Adverse events 
 
Have there been any adverse events since the intervention? Yes 
 
 No 
 
If yes, please complete the adverse event log at the end of the CRF  
 
 
 
Changes to medications 
 
Have there been any changes in medication since the intervention? Yes 
 
 No 
 
If yes, please complete in box below:  
 
 
Extremely dissatisfied Extremely satisfied 
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Visit 5 – Outcome measures at 3 months 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
 
 
 
Outcomes 
 
3 Months Post 
Intervention 
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Visit 5 – Outcome measures at 3 months 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
Patient questionnaire 
To be completed by research assistant 
 
 
Treatments/hospitalisations/medications 
 
Has the patient seen a healthcare professional within the 
past 4 weeks due to pain? 
 
 
 
 _______ 
Emergency 
department visits 
_______ 
Length of stay in hospital 
  
_______ GP appointments 
  
_______ pain clinic 
 
 
 Other (give details): 
  
_______________________________________________________________ 
 
Current analgesics (name of medication, dosage and frequency) 
 
 
 
 
 
 
 
 
Other medications (name of medication, dosage and frequency) 
 
 
 
 
 
 
 
Patient’s expectation of benefit 
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Visit 5 – Outcome measures at 3 months 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
 
How satisfied is the patient with the treatment received?  (circle one) 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
Outcome questionnaires 
 
Has the questionnaire pack (set 3) been completed? Yes 
 
 No 
 
 
 
Adverse events 
 
Have there been any adverse events since the last visit? Yes 
 
 No 
 
If yes, please complete the adverse event log at the end of the CRF  
 
 
 
Changes to medications 
 
Have there been any changes in medication since the last visit? Yes 
 
 No 
 
If yes, please complete in box below:  
 
 
 
Extremely dissatisfied Extremely satisfied 
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
100
Visit 6 – Outcome measures after 6 months 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
 
 
 
Outcomes 
 
6 Months Post 
Intervention 
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Visit 6 – Outcome measures after 6 months 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
Patient questionnaire 
To be completed by research assistant 
 
 
Treatments/hospitalisations/medications 
 
Has the patient seen a healthcare professional within the 
past 4 weeks due to pain? 
 
 
 
 _______ 
Emergency 
department visits 
_______ 
Length of stay in hospital 
  
_______ GP appointments 
  
_______ pain clinic 
 
 
 Other (give details): 
  
_______________________________________________________________ 
 
Current analgesics (name of medication, dosage and frequency) 
 
 
 
 
 
 
 
 
Other medications (name of medication, dosage and frequency) 
 
 
 
 
 
 
 
Patient’s expectation of benefit 
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Visit 6 – Outcome measures after 6 months 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
 
How satisfied is the patient with the treatment received?  (circle one) 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
Outcome questionnaires 
 
Has the questionnaire pack (set 4) been completed? Yes 
 
 No 
 
 
 
Adverse events 
 
Have there been any adverse events since the last visit? Yes 
 
 No 
 
If yes, please complete the adverse event log at the end of the CRF  
 
 
Changes to medications 
 
Have there been any changes in medication since the last visit? Yes 
 
 No 
 
If yes, please complete in box below:  
 
 
 
 
 
Extremely dissatisfied Extremely satisfied 
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End of study 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
 
 
 
 
End of study 
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End of study 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
End of study 
To be completed by research assistant 
 
 
 
Date of final study contact with patient ________________ 
 
Reason (circle one) 
 
Completed study 
Withdrawn from study 
Other 
 
Reason for withdrawal from study (circle one) 
 
Drop out 
Protocol non-compliance 
Adverse event (please complete AE form at the end of the CRF) 
Other 
 
If other, provide further details: 
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End of study 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
 
 
 
 
Adverse events 
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End of study 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
Adverse events 1 
 
 
Date adverse event occurred ________________ 
 
Date investigator become aware of the event ________________ 
 
Location of adverse event 
________________________________________________________________ 
 
Event details: 
 
 
 
 
 
 
 
 
 
 
 
Is the adverse event related to the procedure? (circle one only) 
 
Unrelated 
Unlikely 
Possible 
Probably 
Related 
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End of study 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
Was the adverse event a serious adverse event (SAE)? 
 
Yes 
No (move on to action plan) 
Serious criteria (circle all that apply) 
 
The AE led or could have led to a congenital anomaly/birth defect 
The AE led or could have led to death 
Resulted in medical or surgical intervention to prevent permanent impairment to a body 
structure 
Life-threatening illness or injury 
Resulted in permanent impairment of a body structure or body function 
Required inpatient hospitalisation 
Other 
 
Action plan 
 
No action required 
Amend consent form 
Amend protocol 
Inform current subjects 
Terminate or suspend protocol 
Other 
 
Has the Sponsor been informed? 
 
Yes 
No 
 
If other, provide further details: 
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End of study 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
Adverse events 2 
 
 
Date adverse event occurred ________________ 
 
Date investigator become aware of the event ________________ 
 
Location of adverse event 
________________________________________________________________ 
 
Event details: 
 
 
 
 
 
 
 
 
 
 
 
Is the adverse event related to the procedure? (circle one only) 
 
Unrelated 
Unlikely 
Possible 
Probably 
Related 
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End of study 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
Was the adverse event a serious adverse event (SAE)? 
 
Yes 
No (move on to action plan) 
Serious criteria (circle all that apply) 
 
The AE led or could have led to a congenital anomaly/birth defect 
The AE led or could have led to death 
Resulted in medical or surgical intervention to prevent permanent impairment to a body 
structure 
Life-threatening illness or injury 
Resulted in permanent impairment of a body structure or body function 
Required inpatient hospitalisation 
Other 
 
Action plan 
 
No action required 
Amend consent form 
Amend protocol 
Inform current subjects 
Terminate or suspend protocol 
Other 
 
Has the Sponsor been informed? 
 
Yes 
No 
 
If other, provide further details: 
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End of study 
Patient identification number __________ 
 
Patient initials __________ 
 
Investigator’s initials __________ 
 
Date __________ 
Facet-joint study case report form
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Appendix 9 Literature review to inform the
health economics component and costing
methodology
Literature review
Objectives
A rapid, systematically based review of the health economics literature was conducted to inform the
development of the framework for an economic model to assess the longer-term cost-effectiveness of FJIs
for persistent non-specific LBP. The review identified, and assessed the scope and quality of, the current
evidence in relation to:
1. the cost-effectiveness of FJIs for persistent non-specific LBP
2. specific resources and associated costs associated with FJIs
3. relevant outcomes to inform a health economic analysis, for example health-related quality of life/
utilities – this considered possible candidate measures used elsewhere, for example the EQ-5D or SF-6D
4. possible frameworks, for example economic models, that have been reported in the literature.
Methods
A PICO (problem/population, intervention, control, outcomes) approach was used to generate appropriate
search terms (Table 22). PubMed and the NHS Economic Evaluation Database (NHS EED) were
systematically searched to identify relevant studies (systematic reviews, randomised controlled trials and,
when necessary, observational studies), following key PRISMA principles.13
Cost of illness studies, costing studies or other partial economic evaluations were identified but not
formally reviewed. In addition, searches to identify literature to inform health-related quality of life/utility
estimates were undertaken.
Results
The search strategy identified only two studies65,66 evaluating the cost of FJIs, although these were partial
economic evaluations rather than formal cost-effectiveness studies, and one study37 evaluating health-related
quality of life.
Cohen et al.65 evaluated lumbar z-joint denervation costs and outcomes using three paradigms:
(1) radiofrequency denervation without the use of a screening block; (2) radiofrequency denervation if the
patient obtained significant relief after a single diagnostic block; and (3) radiofrequency denervation only if
an appropriate patient had a positive response to two confirmatory medial branch (facet-joint nerve) blocks
to determine which treatment paradigm was associated with the highest overall and radiofrequency
TABLE 22 The PICO framework for the health economics literature review
Number Problem/population Intervention Control Outcomes
1. facet-joint injection sham cost
2. cervical analgesia placebo effectiveness
3. thoracic denervation standard of care economic
4. lumbar quality of life
5. utilities
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denervation success rates, and to evaluate the relative costs per successful treatment for each of the three
groups. The primary end point as a measure of ‘clinical success’ was 3 months of significant pain relief.
The cost of a diagnostic facet-joint block averaged US$350 for the first level and US$170 for each
subsequent level; the cost of radiofrequency denervation averaged US$650 for the first joint and US$325
for each additional joint; the overall group success rate ranged between 17% and 32%; and the mean
cost of successful treatment in the single-block group was US$5172 (SD US$860). The study found that
proceeding straight to radiofrequency denervation without any diagnostic blocks was associated with both
the lowest cost per successful procedure and the highest number of total successful procedures.
Burnham et al.66 conducted an evaluation of the effectiveness of radiofrequency denervation of the lumbar
facet-joints for pain, analgesic intake, disability, patient satisfaction, back pain-related costs and employment
status in patients with chronic LBP of facet-joint origin in the context of a clinical audit of a new radiofrequency
denervation programme. Both direct and indirect costs relating to LBP care that were or could potentially be
borne directly by the subject were estimated. Direct costs were calculated by asking the subject to describe the
type and number of any of the following treatments/services received for his or her LBP in the previous month:
physician office visits, chiropractic treatments, physiotherapy treatments and treatments from other allied
health practitioners (massage, acupuncture, psychology and so forth).
Post radiofrequency denervation, significant improvements were observed in pain, analgesic requirements,
satisfaction, disability and direct costs occurred. These outcomes peaked at 3–6 months and gradually
diminished thereafter. Satisfaction with medical care and living with current symptoms improved similarly.
Overall, satisfaction with the radiofrequency denervation procedure was high and no complications
were reported.
Based on these outcomes, it was deemed that radiofrequency denervation provides safe and significant
short-term improvements in pain, analgesic requirements, function, satisfaction and direct costs in patients
with chronic LBP of facet origin.
Ribeiro et al.37 studied 60 subjects with a diagnosis of facet-joint syndrome who were randomised into an
experimental group (intra-articular injection of six lumbar facet-joints with triamcinolone hexacetonide) or
a control group (intramuscular injection of six lumbar paravertebral points with triamcinolone acetonide).
No details were provided by the authors on trade names or manufacturer details for the drugs used.
Outcome measures including a pain VAS, a pain VAS during extension of the spine, a Likert scale,
an improvement percentage scale, the Roland Morris Disability Questionnaire and the SF-36 were
administered at baseline and at 1, 4, 12 and 24 weeks after the interventions. The data revealed an
improvement in the experimental group in terms of health-related quality of life, in the ‘role physical’
profile, assessed by the SF-36.
Conclusions
The literature search identified a very limited set of evidence on the cost-effectiveness of diagnostic or
therapeutic FJIs and the studies identified were simple costing studies. As such, a knowledge gap remains
for the simulation of longer-term outcomes to inform cost-effectiveness models with long-term horizons.
Resource use associated with facet-joint injections
Resource use: methodology
The patient questionnaire was completed by a research assistant during visits to a nurse-led outpatient
pain management clinic and took approximately 1 hour to complete. The visits took place at 6 weeks
(visit 4, research study-specific visit), 3 months (visit 5, research study-specific visit) and 6 months (visit 6,
standard routine consultant-led outpatient check-up).
The questions regarding NHS resource use specifically asked about the most likely health-care professionals
who would be engaged with during treatment for LBP; the results are detailed in Table 23.
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Medication
The patient questionnaire contained within the case report form collected information on current
prescribed analgesics and any other medications at baseline. At the three follow-up time points
information on current analgesics and other medications was also collected along with any changes in
medication during the follow-up period. Information on medication use is reported in Table 24.
The specific dates that prescriptions were issued, including the dates that any changes in medication occurred,
are unknown as medications were prescribed by the patients’ GPs rather than by the trial team. Medication
reported in the ‘other’ medication category that was not related to the treatment of LBP was excluded.
Medication costs were calculated at baseline (visit 1) to evaluate the pain medication being taken before
the intervention commenced. Costs were then calculated between baseline and the 6-week follow-up
(visit 4), between visit 4 and the 3-month follow-up (visit 5) and between visit 5 and the 6-month follow-up
(visit 6). As some patients had their pain medication prescriptions changed in the community by their GP
between follow-up visits to the hospital, any change in prescription was assumed to be at the mid-point
between follow-up visits for costing purposes. Table 25 shows how the time periods were classified in days
to calculate the duration of prescribed medication.
The cost of medication per day was calculated and this was then multiplied by the number of days the
medication was prescribed.
TABLE 23 NHS resource use reported via the case report form patient questionnaire
Coded variable
Variable
type
Description of resource use
and basis for the unit cost Unit cost
Unit cost
source
V01 _ Emergency
DepartmentVisits
Number,
long integer
Emergency department visit
(standard A&E attendance)
£137.74 Department
of Health68
V01 _ LengthOfStay Number,
long integer
Length of stay in hospital
(emergency admission as a
result of serious adverse
event)
Unit cost method to be
decided – see data.
National average unit cost:
Non-Elective Inpatients – Long
Stay £3058.14, Non-Elective –
Short Stay £615.83
Department
of Health68
V01 _ GPAppointments Number,
long integer
GP appointment (assumed to
be a standard GP consultation
with an average contact of
9.22 minutes) at a GP surgery
£36 Curtis and
Burns67
V01 _ PainClinic Number,
long integer
Pain clinic (standard routine
outpatient appointment at a
pain management clinic)
Assumed to be consultant
led unit cost – £148.03
(non-consultant-led unit cost
£111.15)
Department
of Health68
A&E, accident and emergency.
TABLE 24 Medication use reported via the case report form patient questionnaire
Coded variable Variable type
Description of resource use and basis
for the unit cost Unit cost source
V01 _ CurrentAnalgesics Text Current analgesics (name of medication,
dosage and frequency)
BNF69
V01 _ OtherMedications Text Other medications (name of medication,
dosage and frequency)
BNF69
BNF, British National Formulary.
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Dealing with missing medication data
Table 26 contains the substitute costing rules applied when reported medication prescriptions were vague
or information was missing. Table 27 lists the analgesic medication reported by trial participants and the
accompanying unit costs.
Calculating quality-adjusted life-years
For both groups in the study the number of QALYs gained was calculated for the complete cases for the
6 months between baseline (before treatment) and the final 6-month follow-up visit, as shown in Table 28.
Existing measures used to collect resource use data in lower back
pain studies
A search of the DIRUM82 to compare existing resource use measures specifically related to LBP was
conducted. The results of this search are shown in Table 29.
TABLE 25 Calculating the length of a prescription for analgesic medication
Time perioda Duration in days
Duration of baseline prescribed medication A period of 21 days before the baseline assessment
(assumption as pretrial duration of prescribed medication is
unknown)
When the same medication was reported at successive
follow-up points the whole period between time points was
considered as a continuous prescription
Baseline (visit 1) to 6-week follow-up (visit 4) = 42 days;
6-week follow-up (visit 4) to 3-month follow-up (visit 5)=
51 days; 3-month follow-up (visit 5) to 6-month follow-up
(visit 6) = 93 days
When a change in prescribed medication was reported an
approximate mid-point between follow-up visits was used to
estimate prescription duration – the previous medication
was allocated the first half of the number of days in that
period and the new medication was allocated the second
half of the number of days during that time period
At visit 4: old medication = first 21 days after baseline
assessment, new medication= the 21 days before visit 4;
at visit 5: old medication = first 25.5 days after visit 4,
new medication = the 25.5 days before visit 5; at visit 6:
old medication = first 46.5 days after visit 5, new
medication = 46.5 days before visit 6
a Total of 180 days or 6-month duration of the trial (assumed 30-day months).
TABLE 26 Substitute costing rules for vague or missing information on medication dose and frequency
Medication dose and frequency of dose is reported
within a possible range depending on need
The lower dose and frequency is used as a
conservative estimate or a maintenance dose is used
Ibuprofen (200 mg) The daily standard maintenance dose is used= two tablets,
three times per day = six tablets = 1.2 g per day
Paracetamol (500mg) The daily standard dose of 500mg every 4 hours= six tablets
per day= 3 g per day
Co-codamol (30/500 mg) A standard dose of two tablets four times a day = eight
tablets per day
Naproxen (250mg) A standard maintenance dose of one tablet every
6 hours = four tablets per day = 1 g per day
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TABLE 27 Medications reported and accompanying unit costsa
Name of
medication Dose Frequency of dose
Unit
cost per
pack (£)
Number
of tablets
per pack
Cost per
tablet (£)
Amitriptyline 10 mg 3 × (at night) 0.96 28 0.034286
Amitriptyline 25 mg 1 × daily 0.99 28 0.035357
Amlodipine 5 mg 1 × daily 0.91 28 0.0325
Co-codamol 30 mg Two tablets each
4 × daily
6.73 100 0.0673
Co-codamol 8/500 mg 4 × daily 1.16 30 0.038667
Co-codamol 30/500 mg Daily as required 6.73 100 0.0673
Codeine 30–60mg BD (2*)/TDS (3*),
depending on severity
1.44 28 0.051429
Codeine phosphate 30/500 mg 6 × daily 6.73 100 0.0673
Diazepam 5mg 1 × nightly 1.06 28 0.037857
Duloxetine 60 mg 1 × nightly 27.72 28 0.99
Duloxetine 60 mg 1 × daily 27.72 28 0.99
Gabapentin 200 mg 2 × daily 3.17 100 0.0317
Ibuprofen 5% gel 3 × daily 1.28 1 1.28
Ibuprofen 400mg 3–4 × daily 3.50 84 0.041667
Lyrica 300 mg Max. 300 mg per day
for neuropathic pain
64.40 56 1.15
Naproxen As needed Assumed standard dose 1.12 28 0.04
Nortriptyline 10 mg 1 × daily 12.06 100 0.1206
Palexia (50 mg) 2 × daily 12.46 28 0.445
Paracetamol 500 mg as required Assumed standard dose 0.92 32 0.02875
Pregabalin 75 mg standard 3 × daily, standard dose
75mg twice daily
64.40 56 1.15
Solpadol Assumed standard dose Assumed standard dose 6.74 100 0.0674
Tremadol
(assumed tramadol)
50 mg 2 × every 4–6 hours 1.20 30 0.04
BD (2*), two times per day; max., maximum; TDS (3*), three times per day.
a Costed according to the British National Formulary.69
TABLE 28 Calculation of QALYs
Time period Calculation method
6 weeks between baseline (visit 1) and 6-week follow-up
(visit 4)
[(EQ-5D mean utility at visit 1+ EQ-5D mean utility at
visit 4)/2] × (6 weeks)=QALYs gained at visit 4
6 weeks between 6-week follow-up (visit 4) and 3-month
follow-up (visit 5)
[(EQ-5D mean utility at visit 4+ EQ-5D mean utility at
visit 5)/2] × (6 weeks)=QALYs gained at visit 5
12 weeks between 3-month follow-up (visit 5) and 6-month
follow-up (visit 6)
[(EQ-5D mean utility at visit 5+ EQ-5D mean utility at
visit 6)/2] × (12 weeks) =QALYs gained at visit 6
Total QALYs gained at the end of treatment QALYs gained at visit 4+QALYs gained at visit 5+QALYs
gained at visit 6
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TABLE 29 Existing resource use measures for lower back pain
Disease category Reference Items of resource use being measured
Anaesthesia and pain control Back Pain Questionnaire91 GP visits, physiotherapy visits, other NHS (osteopath
and chiropractor visits)
Anaesthesia and pain control BeST trial follow-up
questionnaire44
GP visits, inpatient admissions, practice nurse visits,
outpatient attendance, medication, A&E attendance,
physiotherapy visits, psychologist visits, other NHS
(scans, radiography, blood tests), other non-NHS
(private visits: chiropractor, osteopath, physiotherapist,
alternative therapy, etc.)
Anaesthesia and pain control Lower Back Pain Resource
Use Questionnaire92
Inpatient admissions, outpatient attendance, A&E
attendance, employer,a physiotherapy visits, health-
care aids, other non-NHS (chiropractor, acupuncturist
and osteopath visits)
Anaesthesia and pain control,
orthopaedics and trauma
Scottish Back Trial
Questionnaire93
GP visits, inpatient admissions, outpatient attendance,
medication, physiotherapy visits
A&E, accident and emergency.
a This refers to the effect that lower back pain has on employment/current job role.
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Appendix 10 Summary of changes to
the protocol
Amendment Protocol version, date Summary of changes
Minor amendment 4, 4 February 2015 Update to schedule of assessment table
Substantial amendment 1 5, 2 September 2015 Update to patient safety information
Revised details for the TSC and DMC
Substantial amendment 2 6, 7 May 2016 Change of Chief Investigator and Principal Investigator
at Barts Health NHS Trust
Lidocaine renamed as a non-IMP
Additional recruitment from spinal orthopaedic and
musculoskeletal clinics
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Appendix 11 Missing or incomplete
questionnaire data
E leven participants did not complete, or completed incorrectly, the different components of eachquestionnaire; this is detailed in Table 30.
TABLE 30 Missing or incomplete questionnaire data
Participant
number
Missing data
DetailsBaseline 6 weeks 3 months 6 months
1002 All All
1003 BPI ‘What treatments or medications are you receiving
for your pain?’ – missing
1004 BPI ‘Please mark on the diagram the area of your
pain’ – spoiled
1005 SF-12 ‘Climbing several flights of stairs’ – missing
1006 All
1007 Oswestry ‘Social life’ – spoiled
1009 All
1009 SF-12 ‘Physical health, limited to work, emotional
problems, did work less carefully’ – missing
1010 SF-MPQ-2 ‘Hot burning pain, splitting pain’ – missing
SF-12 ‘Did work less carefully’ – missing
Oswestry ‘Personal care, sleeping’ – spoiled; ‘sex life’ –
missing
1011 SPS 6 ‘I felt hopeless about finishing certain work tasks,
due to my health problems’, ‘At work, I was able
to focus on achieving my goals despite my health
problem’ and ‘Despite having my health problem,
I felt energetic enough to complete all my work’ –
missing
1014 EQ-5D-5L ‘Pain/discomfort’ – missing
Oswestry ‘Sex life’ – missing
Oswestry, Oswestry Low Back Pain Disability Questionnaire.
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Appendix 12 Graph showing the number of
patients screened compared with the recruitment rate
by recruitment month
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Appendix 13 Flow diagram showing the actual
compared with the estimated flow of participants
through the study
Patients with non-specific low back pain
(n = 628) estimated 1000
Eligible to enter study
(n = 50) estimated 250
Patients screened and consented
(n = 16) estimated 150
Diagnostic test for facet-joint disease
(n = 11) estimated 150
Six medial branch nerve blocks through a spinal needle using 0.5 ml of
1% lidocaine per injection, under fluoroscopic guidance
Positive diagnostic test
(82%, n = 9) estimated 40%, n = 60
50% or greater pain reduction lasting > 30 minutes
Baseline outcome assessments
Randomisation
Combined physical and psychological
programme and facet-joint injections
(n = 5) estimated 30
Four intra-articular facet-joint injections
through a spinal needle at two bilateral 
lumbar levels, using 0.5 ml of 05.% bupivacaine
 and 20 mg of methylprednisolone per joint, 
under fluoroscopic guidance
Combined physical and psychological
programme and sham procedure
(n = 4) estimated 30
Four peri-articular injections through a
spinal needle at two bilateral lumbar levels,
using 0.5 ml of normal saline per injection,
under fluoroscopic guidance
Outcome assessments at 6 weeks, 3 months and 6 months
(n = 8) estimated 48
Drop-out
(n = 1)
Drop-out
(n = 5)
Negative diagnostic test
(n = 2) estimated 90
Declined to consent
(n = 34) estimated 100
Not eligible
(n = 578) estimated 750
• Previous lumbar 
  facet-joint injections 
  or spinal surgery
• Other dominant pain
   or widespread pain
• Radicular pain
• Pain of ≥ 3 months’ duration
• Pain of ≥ 4/10 in the 7 preceding days
• Signs and symptoms of facet-joint disease including bilateral localised
   paraspinal tenderness at two lumbar levels
• Received two or more components of NICE-defined best non-invasive
   care (education and one of physical exercise programme, acupuncture 
   or manual therapy)
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Appendix 14 Limitations of current resource use
measures and recommendations for improving the
accuracy of capturing future NHS service provision
Resource use Limitations and recommendations
Medication Limitations:
l No data were collected on the duration of time that medication was prescribed
for – specifically, there was no accurate information on the date that medication was
prescribed or the length of time that each prescription was intended for. As pain
medication can be taken for a prolonged length of time, each repeat prescription
should also be noted for accurate costing
l Information on the dose and the number of times per day that the dose is to be
taken was sometimes vague or missing
Recommendations:
l The prescribed dose, the prescribed number of times per day that the dose is to be
taken and the number of days per prescription should be documented
l Ensure that the names of medications are accurate
Visits to health-care professionals
Time scale of data capture at
follow-up
Limitation:
l The follow-up periods were 6 weeks, 3 months and 6 months post intervention.
However, the question on the case report form asked patients to report visits to
health-care professionals within the last 4 weeks prior to the follow-up data
collection session. This would not capture visits prior to that 4-week window
Recommendation:
l Amend the question regarding duration to include the whole period before the
follow-up data collection session to capture all resource use information
Hospital inpatient stay Limitation: no information on mode of admission or reason for admission
Recommendation:
l To facilitate the costing of secondary care resource use, sufficient clinical information
should be collected so that the correct Healthcare Resource Group (HRG) codes from
NHS reference costs can be used for accurate costing. Such information includes
the following:
¢ Mode of admission:
– elective inpatient admission mean cost, £3749.81
– non-elective inpatient admission short stay (< 24 hours in hospital) mean
cost, £615.83
– non-elective inpatient admission long stay (≥ 1 day/night in hospital) mean
cost, £3058.14
– day case/surgery mean cost, £733.31
¢ Clinical reason for admission:
– review HRG codes in advance to select the most pertinent to the trial
procedure/population
DOI: 10.3310/hta21740 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 74
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Snidvongs et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
129
Resource use Limitations and recommendations
Emergency/A&E attendances Consider the type of service that trial participants are likely to require. Would they be
admitted or treated and discharged? What is the level of investigation and treatment?
Treatment and discharge is less costly than treatment and admittance. The construction of
appropriate questions to capture information on attendance should be considered if this
area of health-care resource use is an important driver of costs for the trial population.
If not considered an important cost driver an average cost of £137.74 per attendance can
be applied for simplicity
Ambulance service Consider if trial participants would be potential users of the ambulance service and the
implications of service type and associated costs:
l Calls, £7
l Hear and treat or refer, £34
l See and treat or refer, £181
l See and treat and convey, £236
Outpatient clinics Note in advance the type of service-led clinic if relevant. For example, a consultant-led
outpatient clinic is more expensive than a non-consultant-led clinic
GP consultations Limitation:
l No information on mode of consultation
Recommendation:
l GPs consult with patients in various ways, which is particularly important for patients
with long-term chronic conditions
l Patient attends GP practice appointment, £36
l GP telephone call to patient, £14.60
l GP visits patient at home, £45 (2015 unit price)
A&E, accident and emergency.
Secondary care, hospital-based costs were derived from NHS Reference Costs 2015 to 2016.68 Contains public sector
information licensed under the Open Government Licence v3.0.
Primary care GP costs were derived from Curtis and Burns.67
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